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Abstract 
The promise of D N A vaccination is limited in part by invasive, untargeted 
administration. We refined the strategy by incorporating attenuated bacteria to 
deliver plasmids directly to APCs. 
Initial studies involved human macrophages, which were infected with aroA-
Salmonella typhimurium transformed with eukaryotic vectors encoding 8-
galactosidase. Results of staining with x-gal demonstrated effective transfer of 
plasmids to the target cells, which expressed the reporter gene themselves. Similarly, 
immunocytochemical staining of macrophages infected with bacteria bearing a 
eukaryotic vector encoding HIV-1 env showed expression of the viral gene. 
Macrophages were also infected with bacteria harboring vectors encoding SIV 
env and HIV-1 tat, then subjected to lysis, RNA extraction and RT-PCR. In this way, 
conceptual proof of the system was achieved at the level of transcription. Indeed, in 
the latter case, we recovered a splice product, which specifically confirms eukaryotic 
expression. 
Further studies involved human DCs, cultivated from PBMCs in vitro. We 
first used flow cytometry to show that infection with Salmonella induces maturation, 
a state ultimately necessary for immunogenicity. Once again, bacteria carrying B-
galactosidase vectors were used initially. DCs were also infected with bacteria 
carrying a vector encoding HIV-1 gag, then stained for expression of the viral 
protein. Both immunocytochemistry and flow cytometry confirmed Gag expression. 
Finally, transduced DCs were co-cultivated with autologous T-cells in studies 
aimed at detecting interferon-7 expression as a gauge of antigen presentation. 
Bacteria were first transformed with eukaryotic vectors encoding influenza Ml 
protein. PBMCs were therefore obtained from donors known to have memory 
responses to influenza. Co-cultures yielded significant T-cell responses (by ELISpot 
and flow cytometry) to DCs transduced to express Ml. We next obtained PBMCs 
from HIV-1-infected donors, setting up co-cultures involving DCs infected with 
bacteria carrying HIV-1 gag vector. Again, significant T-cell responses were 
detected when DCs were transduced to express the viral protein using Salmonella. 
Thus, using attenuated S. typhimurium, we can deliver vectors encoding 
foreign antigens directly to human APCs. DCs transduced to express viral proteins 
can present antigen to autologous T-cells in vitro. As a vaccine tool, this strategy 




THE QUEST FOR A VACCINE AGAINST HIV-1 
Despite over two decades of effort against it, the global HIV-1 epidemic 
continues to plague humanity (1). In the face of such an unprecedented medical 
challenge, the scientific community has made important advances in virology, 
immunology and pharmacology. Nonetheless, it has proven extremely difficult both 
to contain the spread of infection around the world, and to prevent disease 
progression in most infected individuals. 
As a retrovirus, HIV-1 presents us with unique obstacles to vaccine design (2, 
3). Unlike other viral pathogens, for example, HIV-1 integrates into the host cell 
genome and therefore remains hidden from the immune system as latent proviral 
DNA. Furthermore, viral particles are camouflaged by their heavily glycosylated 
envelopes. Those proteins that are effectively exposed as potential immune targets 
are highly variable. Indeed, HIV-1 has a substantial degree of genetic diversity, as 
well as antigenic heterogeneity. Additionally, the virus employs mechanisms towards 
immune evasion, including the shedding of "decoy" monomeric envelope proteins 
and the induction of MHC downregulation. Finally, and perhaps most key for viral 
persistence within the host, HIV-1 targets the very cells of the immune system that 
would otherwise be its foil: A definitive hallmark of .AIDS pathogenesis is the 
destruction of CD4+ T-cells. 
Apart from fundamental problems posed by the nature of the virus itself, we 
as scientists also face practical challenges imposed by the limitations in our own 
knowledge and technology. An accurate animal model for AIDS and realistic 
challenge virus are not available, for example, despite the significant utility of rhesus 
macaques and SIV/SHIV (4). More importantly, we have not yet defined the human 
responses that confer protection from HIV-1 disease: What are the immune correlates 
of protection in so-called "long-term non-progressors (LTNPs)" and exposed but 
uninfected individuals? After 20 years of careful scrutiny of these rare cases, we do 
not have an unequivocal answer. (5). 
When HIV-1 was first identified, our understanding of immune responses was 
in fact relatively poor. Thus, early attempts to design a vaccine against the virus 
were, in retrospect, misguided, and certainly informed by empiricism above all else 
(6). More recent vaccine candidates represent technologies that have emerged only 
since the AIDS epidemic began (2). Despite reason for hope, we remain confronted 
by the essential question of whether an effective vaccine will be possible at all (6). In 
the case of previous viral pathogens, in contrast to HIV-1, it was always clear to 
vaccinologists that people who survived acute infection would go on to be immune to 
subsequent threat from the same virus. With very few examples of natural immunity 
to HIV-1, we lack absolute indicators to guide us in vaccine development (7). 
Furthermore, we must accept that sterilizing immunity against HIV-1 may never be 
possible (8). Rather, it is likely that the general goal of prophylactic immunization 
should be to prime immune responses that will allow the host to contain the pathogen 
after initial infection (7). 
Approaches to HFV-1 vaccine design, therefore, have been necessarily 
creative. Established strategies such as live attenuated viruses, inactivated viruses 
and subunit vaccines have proven inadequate or unsafe; thus, newer, innovative 
technologies continue to be actively investigated (2, 6-8). These experimental 
vaccines include live recombinant vectors (pox viruses, adenoviruses, etc.) and DNA 
plasmids. As a prime-boost regimen, in fact, the combination of these two novel 
approaches has proven especially hopeful (2, 7). 
In and of itself, however, DNA vaccination seems a whimsical and unlikely 
strategy (9). Nonetheless, its great simplicity, practicality and potential for versatility 
have inspired a persistent effort to develop the technique for clinical use. Despite 
some promise of in vivo efficacy, there continues to be much speculation as to precise 
mechanism of action. Most studies suggest that injected vaccine plasmids are 
received and expressed by non-lymphoid tissue with subsequent antigen transfer to 
professional antigen-presenting cells (10-12). Limitations of the approach include 
invasive administration, untargeted delivery and only modest levels of in situ protein 
expression. Many groups have therefore undertaken to refine the strategy towards 
enhancing DNA vaccine-elicited immune responses (13, 14). 
S A L M O N E L L A A S A V A C C I N E T O O L 
Despite the predominant tendency for infectious pathogens to be transmitted 
mucosally, most vaccines approved for human use in the United States must be 
administered invasively (Table 1). Indeed, since the discontinuation of the oral 
(Sabin) polio vaccine in 2000 (15), the only oral vaccine approved for use in the U.S. 
is live attenuated Salmonella typhi, which works against typhoid fever. Among the 
few newer vaccines that have been approved in recent years, there is one other 
mucosally-administered preparation: a live attenuated influenza virus for intranasal 
use. Salmonella, however, is the only live bacteria used as a vaccine (though Vibrio 
and Mycobacteria are employed in other parts of the world). 
Perhaps, then, it is in part because Salmonella spp. were already in place as 
clinical agents that several groups undertook to explore their potential use as tools of 
vaccination against other pathogens. Attenuated Salmonella has, for example, been 
engineered to express heterologous antigens from HIV, SIV, influenza, Listeria, 
pertussis toxin and cholera toxin (16-25). It is clear, however, that serving as in situ 
protein-expression vectors is not the bacteria's greatest strength in this context. 
Rather, it is more important to consider the advantages of exploiting Salmonella as 
vaccine-delivery vehicles. 
The need for effective new vaccine adjuvants for use in strategies against 
HIV-1 is well-established (26), and there is particular interest in the development of 
T A R G E T 
diphtheria/tetanus 
meningococcus 
yellow fever virus 
Salmonella typhi (typhoid fever) 
rabies virus 
hepatitis B virus (HBV) 
hepatitis A virus (HAV) 
diphtheria/tetanus/pertussis 
diphtheria/tetanus/pertussis/HBV/poliovirus 
H A V / H B V 
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Table 1 Vaccines currently in use in the United States Source: PDR, 58 
edition (2004) (27) EVAintramuscular, SC=subcutaneous, VO=per os (oral), 
ENAntranasal. 
th 
mucosal adjuvants (28-30). A n adjuvant m a y enhance the efficacy of a vaccine in 
more than one way, including by modifying the micro-environment to render it more 
receptive to the immunogen (e.g., by serving as a chemoattractant for relevant cells), 
or by facilitating and targeting delivery of the vaccine itself. Salmonella as a vaccine 
carrier would therefore be functional as its own adjuvant on both levels. 
Lymphotropic, intracellular pathogens, the bacteria naturally home to gut-associated 
lymphoid tissue, where their endotoxin and invasive behavior make them a 
provocative immune stimulus in situ. In fact, other bacterial antigens (including 
cholera toxin and E. coli heat-labile enterotoxin) are widely used experimentally in 
animals as mucosal adjuvants, but generally deemed too toxic for human use (30). 
Importantly, Salmonella would also effectively overcome the baseline tolerogenic 
response of the gut towards antigen received into the lumen (31). Administration, 
like that of the existent mucosal vaccine against typhoid fever, would mimic natural 
Salmonella transmission through the oral route. 
The current project, then, represents an attempt to build on the idea of using 
attenuated Salmonella as a vaccine vector by using the bacteria instead as vaccine 
vehicles. As an experimental approach, conventional DNA vaccination offers no 
possibility for non-invasive administration or guided delivery. Furthermore, the 
generation of mucosal immunity is very unlikely with direct intramuscular or 
subcutaneous injection of plasmids. If, however, we use Salmonella to carry and 
deliver our DNA vaccine vectors, we may circumvent these limitations, and further 
enhance immunogenicity with built-in bacterial adjuvanticity. First, however, w e 
must confirm the conceptual design of this model and evaluate its efficacy in vitro. 
Chapter II: 
Materials and Methods 
B A C T E R I A 
Growth 
The attenuated Salmonella typhimurium aroA- strains 33275 and 14028 were 
kindly provided by Stanley Lin (Vion Pharmaceuticals, Inc., New Haven, CT). 
Bacteria were cultivated on solid and in liquid LB medium supplemented with 
antibiotics (tetracycline, ampicillin or kanamycin) 50-lOOftig per mL, as appropriate. 
Extended storage was in 10% glycerol solution at -70°C. 
Transformation 
Salmonella were grown to logarithmic phase then rendered electro-competent 
by chilling on ice and washing three times with sterile H20. Bacteria were then 
concentrated to 5.0 x 1010 - 1.0 x 10u/mL for transformation. Electroporation was 
carried out using the Gene Pulser II (Bio-Rad Laboratories, Inc., Hercules, CA) with 
cuvette gap 0.1cm, 1.8kV, 25/xFD, 200Q and a time constant of 4-6msec. Each 
reaction involved 50/xL of bacterial solution and 0.5 - 2.0/Ag DNA. Following 
electroporation, bacteria were grown for 1 hour in SOC medium before being plated. 
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Quantification of bacterial density 
Correlation of optical density (OD) and Salmonella concentration was 
achieved by serial dilutions and plating on solid medium. It was thereby concluded 
that an OD600 of 0.8 is approximately equivalent to 2 x 108 bacteria per mL. 
Quantification of plasmid content 
Salmonella transformed with plasmids of various sizes were grown to an 
OD600 of 0.8. The QIAprep Spin Miniprep Kit (Qiagen, Inc., Valencia, CA) was then 
used to extract extra-genomic DNA from bacterial solutions of different volumes. An 
OD260 of 1.0 was considered equivalent to 50jU,g/mL, and 1-ug of lOOObp of DNA was 
equated with 9.1 x 10" molecules (as per New England Biolabs, Beverly, MA). In 
this way, it was determined that each transformed bacterium carries 300-900 
plasmids. 
Infectious protocols 
Salmonella were grown overnight at 37°C, then diluted ~1:20 and grown 
another 3-4 hours to desired OD. Cells to be infected were washed and incubated 
with antibiotic-free medium (RPMI 1640 supplemented with serum, L-glutamine and 
Hepes buffer). (Macrophages were left in their original wells in 6-well plates; 
dendritic cells were ultimately seeded at 2 x 106/500/iL into Eppendorf® 1.5mL 
11 
tubes.) Cells were infected with the bacteria at desired multiplicities of infection, 
then incubated at 37°C for 1 hour. Post-infection, cells were washed 2-3 times with 
gentamicin-containing buffer (PBS or HBSS), then incubated in fresh culture medium 
as described below. (Dendritic cells were re-plated in medium containing cytokines 
at 106/2mL of 12-well plates.) When tetracycline-sensitive Salmonella (33275) were 
used, 10/xg of tetracycline was added to each well. 
C E L L C U L T U R E 
Human blood samples 
The New York Blood Center supplied "Leukopacks" derived from 
anonymous donors. Whole blood samples were obtained from consenting adult 
volunteers, some of whom are part of a cohort of HIV-infected patients seen at the 
Rockefeller University Hospital outpatient clinic under the supervision of Dr. Martin 
Markowitz. 
Isolation of peripheral blood mononuclear cells (PBMCs) 
PBMCs were isolated as a buffy coat from human blood samples (or packed 
leukocytes) using Ficoll-Hypaque gradient (Robbins Scientific, Sunnyvale, CA). 
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H u m a n macrophage cultivation 
PBMCs were washed with HBSS and seeded at ~3 x IO7 cells/well of 6-well 
plates in RPMI 1640 supplemented with 1% penicillin-streptomycin, 1% L-
glutamine, 1% Hepes buffer and 5% heat-inactivated autologous serum. Medium was 
changed every two days. Adherent cells were infected as above on day 8 and assayed 
in the same wells. 
Human dendritic cell cultivation 
PBMCs were subjected to CD 14+ selection using magnetic beads and 
columns in accordance with the manufacturer's instructions (Miltenyi Biotec, 
Auburn, CA). CD 14+ cells were then seeded at 2 x lOVwell of 6-well plates in RPMI 
1640 supplemented with 1% penicillin-streptomycin, 1% L-glutamine, 1% Hepes 
buffer, 1% heat-inactivated autologous serum (or 5% type AB human serum (Sigma, 
St. Louis, MO)), recombinant granulocyte-macrophage colony stimulating factor 
(lOOIU/mL; Leukine, Immunex, Seattle, WA) and recombinant EL-4 (20ng/mL; 
R&D Systems, Minneapolis, MN). Additional cytokines were added to the cultures 
at the same concentration every 2 days. Immature dendritic cells were infected as 
above on day 6-8. Mature dendritic cells were obtained by adding IL-1/3, TNF-a. and 
IL-6 (R&D Systems, Minneapolis, MN) at lOng/mL, and prostaglandin E2 (Sigma, St. 
Louis, MO) at Ipg/mL. 
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Dendritic cell/T-cell co-cultivation 
After CD 14+ selection, CD 14- cells were cryopreserved in freezing medium 
(Gibco, Grand Island, NY) to be used as a source of autologous bulk T-cells once 
dendritic cell cultivation was complete. Cells were then defrosted and seeded into the 
wells of a 96-well plate at 2 x IOVIOOjuL (in early studies) or into the wells of a 48-
well plate at 1.2 x 106/500/nL (in later studies). 
Just after peptide pulsing or influenza infection, or approximately 40 hours 
after Salmonella infection, dendritic cells were added to achieve the desired ratio 
(1:30 in early studies, with final volume of 200/-IL in wells of 96-well plates; or 
1:60/1:30 in later studies, with final volume of lmL in wells of 48-well plates). 
Culture medium used in DC/T-cell co-cultures was RPMI 1640 supplemented with 
1% penicillin-streptomycin, 1% L-glutamine, 1% Hepes buffer and 5% type AB 
human serum (Sigma, St. Louis, MO). 
Cultivation of murine dendritic cells from bone marrow 
Marrow from the femurs and tibias of mice were harvested by flushing the 
epiphyseal and medullary cavities with RPMI 1640 using a 3cc syringe fitted with a 
25ga x 5/8" needle (BD, Rutherford, NJ). One volume of 1.66% aqueous NH4C1 was 
added, followed by incubation on ice for 5 minutes. Antibodies to CD4 (TIB 207, 
clone GK 1.5, ATCC, Rockville, MD), CD8 (TIB 150, clone H02.2, ATCC), 
14 
CD45RB (B220 isoform; TIB 146, clone RA3-3A 1/6.1, A T C C ) and M H C H (TIB 
229, clone B21-2, ATCC) were added (as hybridoma supernatants, at a 1:20 dilution) 
to encourage complement-mediated lysis of differentiated lymphocytes and class II 
MHC+ cells. Rabbit complement (Pel-Freez Clinical Division, Rogers, AR) was also 
added at a 1:15 dilution, and cells were incubated for 1 hour at 37°C. After washing, 
cells were plated in 24-well plates at ~1 x lOVwell. Medium used was RPMI 1640 
supplemented with L-glutamine, 5% heat-inactivated FCS (Gemini Bioproducts, 
Calabasas, CA), 1% Hepes buffer, 20ptg/mL gentamicin, 50juM 2-mercaptoethanol 
and 666u/mL of recombinant murine granulocyte-macrophage colony stimulating 
factor (Kirin Brewery Co., Maebashi, Gunma, Japan). Medium was changed every 
two days. 
A S S A Y S 
j8-galactosidase detection with 5-bromo-4-chloro-3-indolyl galactopyranoside (x-
gal) 
Cells to be stained (macrophages or dendritic cells) were incubated with 1% 
formaldehyde and 0.2% glutaraldehyde in PBS for 5 minutes at room temperature, 
then washed twice with PBS. Staining for /3-galactosidase expression was achieved 
by then incubating with 4mM potassium ferrocyanide, 4mM potassium ferricyanide, 
ImM magnesium chloride, and 0.4mg/mL x-gal in PBS for 1 hour at 37°C in a non-
C02 incubator. Staining was stopped by replacing the solution with PBS. 
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Macrophages were kept in their wells for this procedure. Dendritic cells were 
either kept in wells, or affixed to a slide using a "cytospin" technique. This 
preparation was achieved using "Cytofunnels" and a Cytospin II centrifuge (Shandon, 
Pittsburgh, PA). Briefly, 1.0 x IO4 - 1.0 x IO5 cells in 100-150/xL were spun onto 
glass slides at 900rpm for 3 minutes. The slides were air-dried for at least 1 hour, 
then fixed (stabilized) in 100% acetone for 10 minutes before being air-dried once 
again. 
Immunocytochemistry 
Cells were stained using the Vectastain® ABC-AP Kit (Vector Laboratories, 
Burlingame, CA). Briefly, cells (either in wells or on slides) were first incubated 
with blocking (goat) serum for 20 minutes, then with primary antibody (1:500 
dilution of HIV-infected patient's serum) for 30 minutes. Cells were then washed 5-
10 times with PBS, and incubated for 30 minutes with biotinylated secondary (goat 
anti-human) antibody. Finally, cells were incubated with the Vectastain® -ABC-AP 
Reagent (avidin-biotinylated enzyme complex) for 30 minutes, then washed and 
incubated 20-30 minutes with an alkaline phosphatase substrate (Vector® Red). 
Flow cytometry 
/3-galactosidase activity in dendritic cells was detected with the 
DetectaGene™ Green CMFDG lacZ Gene Expression Kit (Molecular Probes, Eugene 
16 
OR). Briefly, cells were hypertonically loaded with fluorescein di-/3-D-
galactopyranoside (FDG), a fluorescent substrate of the enzyme. Additionally, 
chloroquine was added (to raise lysosomal pH, thereby inhibiting endogenous 8-
galactosidase activity), as well as propidium iodide (to identify and exclude dead 
cells) and verapamil (to enhance signal by blocking efflux of fluorescent reaction 
product). 
All antibodies used in interferon-7 assays were obtained from BD-Pharmingen 
(San Diego, CA) at dilutions recommended by the supplier. Cells were collected 
from DC/T-cell co-cultures, pelleted and re-suspended in lmL of medium in 5mL 
polypropylene tubes. In studies using cells derived from HIV-infected patients, the 
co-stimulatory antibodies aCD28 and oCD49d were added (0.5/jiL/mL), as well as 
relevant peptides or the superantigen staphylococcal enterotoxin B (SEB) (Sigma, St. 
Louis, MO) as a positive control for the assay. The cells were then incubated for 6 
hours in the presence of 10.ug/mL brefeldin A (Sigma, St. Louis, MO) at 37°C with 
tubes at a 5° angle. At the conclusion of this incubation, 2-uL EDTA was added to 
each tube, followed by a 15 minute incubation at room temperature. Cells were then 
lysed by the addition of FACS Lysing Solution (BD-Biosciences, San Diego, CA) 
followed by another 15 minute room temperature incubation. Permeabilization was 
achieved by re-suspension and washing with 0.1% saponin and 0.1% bovine serum 
albumin in PBS. Staining with relevant antibodies was carried out at room 
temperature for 45 minutes, before washing with the permeabilization solution and 
fixation with 1% paraformaldehyde in PBS. Flow cytometry was performed using a 
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FACS Calibur instrument, and flow cytometric analysis using CELL-Quest software 
(Becton Dickinson Immunocytometry Systems, San Jose, CA). 
ELISpot 
MultiscreenHTS Filter Plates (Millipore, Billerica, MA) were used for both 
human and mouse assays. For the human interferon-7 ELISpot, plates were coated 
with anti-human-interferon-7 1-D1K capture antibody (Diapharma, Mabtech, 
Stockholm, Sweden) at a 1:100 dilution in 0.1M NaHC03 buffer (pH=9.5), 100/uL per 
well. For the mouse interferon-7 ELISpot, anti-mouse interferon-7 antibody (R&D 
Systems, Inc., Minneapolis, MN) was diluted 1:40 in 0.1M NaHC03 buffer, 
100/iL/well. Plates were then washed 4 times with 0.05% Tween 20 in PBS, then 
blocked with 10% FCS/RPMI1640 (mouse assay) or 5% human serum/RPMI 1640 
(human assay), 100juL/well for 1-2 hours at 37°C. Blocking medium was then 
removed, and wells were seeded with cells, 150-200 pL total volume per well (0.5-
1.0 x IO6 cells [e.g., splenocytes]/well for mouse assay; 1.0-2.0 x 105 CD14- T-cells 
for human assays, with the addition of dendritic cells for varying ratios). Plates were 
then incubated overnight at 37°C to allow for antibody capture. On the following 
day, plates were washed 4-5 times with 0.05% Tween 20/PBS, then incubated with 
detection antibody. For the human assay, biotinylated antibody (7-B6-1 -biotin; 
Diapharma, Mabtech, Stockholm, Sweden) was diluted 1:1000 in PBS, then added 
50-uL/well; the mouse antibody (R&D Systems, Inc., Minneapolis, MN) was diluted 
1:60 in 1.0% BS A/PBS and added 100^L/well. Human assays were then incubated at 
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37°C for 2 hours; mouse assays were incubated at this stage overnight at 4°C. Both 
types of assay were next washed again 4 times with 0.05% Tween 20/PBS, then 
developed using a blue color Development Module (R&D Systems, Inc., 
Minneapolis, MN). ELISpots were read using a plate-reader and ImmunoSpot® 
Software (Cellular Technologies Ltd., Cleveland, OH). 
Peptides 
A complete set of consensus subtype B HIV-1 Gag was obtained from the 
NIH AIDS Research & Reference Reagent Program as 15-mers overlapping by 11. 
Lyophilized protein was solubilized and pooled, to be ultimately used at 2jU.g/mL. In 
co-cultures involving cells from HIV-infected donors, dendritic cells used for positive 
control were first incubated with the Gag peptide pool for 1 hour at 37°C (in plain 
RPMI 1640), then seeded into wells already containing autologous CD 14- T-cells. 
Additionally, for re-stimulation prior to intracellular cytokine staining and flow 
cytometry, Gag pool was added directly to co-culture cells and incubated with 
brefeldin A for 6 hours at 37°C as previously described. 
Influenza virus 
Purified human influenza virus (X:31, A/Aichi/68 [H3N2]) was obtained from 
Charles River Laboratories (North Franklin, CT). For interferon-7 ELISpot and 
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intracellular cytokine staining assays to detect memory T-cell responses to influenza 
matrix protein (Ml), influenza-infected autologous dendritic cells provided both the 
positive control (in co-culture) and the source of re-stimulation (for all co-culture 
categories). Cells were thus infected at a multiplicity of infection approximately 
equal to 2 in RPMI 1640 at 37°C for 1 hour. 
P L A S M I D S 
pTrc-/S and pSLICK-z 
/3-galactosidase vectors were kindly provided by Stanley Lin (Vion 
Pharmaceuticals, Inc., New Haven, CT). pTrc-/3 encodes the reporter gene under the 
control of a prokaryotic Trp-lac hybrid promoter; pSLICK-z encodes the gene under a 
CMV promoter. Both plasmids also code for ampicillin resistance. 
pVAXlfRYVgag 
pVAXl/HIVgag was kindly provided by Yaoxing Huang (Aaron Diamond 
AIDS Research Center, The Rockefeller University, New York). It was constructed 
by first "codon optimizing" HIV-1 subtype C gag (32-34), then inserting the gene 
into pVAXl (Invitrogen, Carlsbad, CA) along with leader sequences (35, 36). The 
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plasmid therefore encodes HIV-1 gag under a C M V promoter; it contains a pMBl 
origin, BGH polyadenylation signal and kanamycin resistance gene. 
penv-gag 
penv-gag was kindly provided by Yaoxing Huang (Aaron Diamond AIDS 
Research Center, The Rockefeller University, New York). It was constructed by first 
modifying the pVAXl vector (Invitrogen, Carlsbad, CA) as follows. The hEFla. 
promoter was PCR amplified from pBudCE4.1 (Invitrogen), then cloned into the 
EcoRl/Notl site, such that a dual-promoter vector was created. "Codon-optimized" 
HIV-1 subtype C env and gag were then inserted, resulting in a vector encoding both 
viral genes under separate promoters. The vector also contains a pMBl origin, BGH 
polyadenylation signal and kanamycin resistance gene. 
Ml vector 
A vector encoding influenza matrix protein (Ml) was kindly provided by 
Thomas Moran (Mount Sinai School of Medicine, New York). It was constructed by 
inserting a gene encoding Ml (WSN strain source) into pCAGGS.MCS (37-40). The 
viral gene is therefore under the control of the chicken /3-actin promoter; the vector 
also encodes an ampicillin resistance gene. 
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pCDNA3.1/SIVe«v and pCDNAl.l/HIVtafrevenv 
Vectors encoding SIV env and HIV-1 tat, rev and env were kindly provided 
by Zhiwei Chen (Aaron Diamond AIDS Research Center, The Rockefeller 
University, New York). Construction of the vectors involved inserting the env gene 
from SIVinac239 into pCDNA3.1 (Invitrogen, Carlsbad, CA). Similarly, the region of 
the HIV-1 (subtype C) genome comprising env, as well as both tat exons and both rev 
exons was inserted into pCDNAl.l (Invitrogen, Carlsbad, CA). Both vectors contain 
a CMV promoter and ampicillin resistance gene. 
RT-PCR 
SIV env 
For RT-PCR amplification of SIV env, R N A was extracted from cells using 
the RNeasy® Mini Kit (Qiagen, Valencia, CA). The RNase-Free DNase Set (Qiagen, 
Valencia, CA) was incorporated into the protocol, as per manufacturer's instructions. 
Reverse transcription was then carried out using Superscript™ RNase H-Reverse 
Transcriptase (GibcoBRL Life Technologies, Invitrogen, Carlsbad, CA). Nested 
PCR was then performed using the following primers: 
EF1 5'-ACATTCATGTGGACAAATTGCAGAGGAGA-3' 
EF2 5 '-TACTGCAAAATGAATTGGTTTCTTAATTGG-3' 
ER1 5'-GGGAGGGGAAGAGAACACTGGCCTATA-3' 
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P C R was done in a Perkin-Elmer 9600 thermocycler (Perkin-Elmer, Foster City, C A) 
in 100/xL volumes containing 0.5 to 1.0/tg of DNA, lOmM Tris-HCl (pH=8.5), 50mM 
KCI, 1.5mM MgCl2, 0.1% Triton X-100, 200 pM each dATP, dGTP, dCTP and 
dTTP, 20pmol of each primer and 2.5U of Taq polymerase. The first round of PCR 
consisted of an initial cycle at 95°C for 2 minutes, followed by 30 cycles of 95°C for 
20 seconds, 45°C for 1.5 minutes and 72°C for 2 minutes, using primers EF1 and 
ER1. The second PCR round, using primers EF2 and ER1, consisted of another 30 
cycles of 94°C for 20 seconds, 55°C for 1.5 minutes and 72°C for 8 minutes. 
HIV-1 tat 
For RT-PCR amplification of spliced HFV-1 tat, RNA was extracted from 
cells using the Oligotex Direct RNA Mini Kit (Qiagen, Valencia, CA). Reverse 
transcription was then carried out using Superscript™ II reverse transcriptase 
(GibcoBRL Life Technologies, Invitrogen, Carlsbad, CA). PCR was then performed 
using the following primers: 
TE 1 5' - ATGG AGCC AGT AG ATCCT AACCT AGAGCC-3' 
TE2 5' -CT AATCGAATGGATCTGTTTTTGTCTTGC-3' 
PCR was done in an Eppendorf Mastercycler Gradient (Brinkmann, Westbury, NY) 
in 50-nL volumes containing 0.5-1.Ojug of DNA, 5pL PCR Buffer II (Perkin-Elmer, 
Foster City, CA), 1.5mM MgCl2, 200/iM each dATP, dGTP, dCTP and dTTP, 
20pmol of each primer and 0.5.uL Gold taq polymerase (Applied Biosystems, Foster 
City, CA). PCR consisted of an initial cycle at 95°C for 10 minutes, followed by 40 
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cycles of 95°C for 15 seconds, 58°C for 30 seconds and 72°C for 30 seconds, 
concluding with an incubation of 72°C for 10 minutes. 
M I C E 
BALB/c and C57BL/6 
B..ALB/C and C57BL/6 mice were purchased from The Jackson Laboratory 
(Bar Harbor, ME). 
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Chapter III: 
Human macrophages can be transduced in vitro using attenuated 
Salmonella typhimurium 
INTRODUCTION 
Salmonella enterica serovar Typhimurium (S. typhimurium) is a facultative 
intracellular pathogen whose preferred host cell is the macrophage (41). Wild-type 
Salmonellae, in fact, persist and thrive within the cells (42), which is precisely what 
permits them to eventually cause systemic disease (43). The bacteria adhere to and 
actively invade macrophages, thereby triggering a cascade of intracellular events that 
are associated with cellular activation (44). Using type HI pili, Salmonellae directly 
deliver effector proteins to the macrophage (41), a property apparently not shared by 
other species of gram-negative bacteria (44). 
A block in the common aromatic biosynthesis pathway yields auxotrophic 
Salmonellae that require aromatic metabolites for survival. Two such metabolites, 
paraaminobenzoic acid and dihydroxybenzoic acid, are not available in mammalian 
tissues; thus, bacteria that are aroA- mutants, for example, cannot grow and are 
avirulent to their hosts (45). After only a few rounds of division, such auxotrophs die 
intracellularly because of their inability to synthesize the aromatic amino acids they 
need to replicate (46). Because they are attenuated and non-pathogenic, aromatic-
dependent Salmonellae have been judged worthy of consideration as anti-bacterial 
vaccine candidates (45, 47). 
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R E S U L T S 
Attenuated Salmonella can deliver a reporter gene vector to human 
macrophages: eukaryotic expression of /3-galactosidase detected by incubation 
with a substrate 
We were interested in developing Salmonella as an instrument with which to 
improve genetic immunization. We hypothesized that we could design a system 
wherein attenuated bacteria are used as plasmid-delivery vehicles. Rather than 
exploit the protein expression machinery of the bacteria themselves, we would 
harness auxotrophic Salmonellae to carry and deliver DNA vaccines to appropriate 
target cells (Figure 1). 
We began, therefore, by using electroporation to transform aroA- Salmonella 
(strain 33275) with each of two vectors, "pTrc-/3" and "pSLICK-z." Both encode the 
/3-galactosidase gene, but the former has a prokaryotic (Trp-lac hybrid) promoter, 
while the latter uses a CMV promoter (See Chapter II). Observation of the 
transformed bacteria in different media confirmed promotional specificity in the 
context of these vector backbones: Salmonellae carrying pTrc-/3 can express 8-
galactosidase; the same strain of Salmonella carrying pSLICK-z cannot. AroA-
Salmonellae were also transformed with other, unrelated vectors (e.g., pEGFP) or left 
untransformed altogether. 
Primary human macrophages were cultivated in vitro from peripheral blood 
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Figure 1 H o w the system would work We envisioned using attenuated S. 
typhimurium to deliver D N A vaccines directly to antigen-presenting cells (APCs). 
Bacteria invade the cell or are actively phagocytosed (1). The auxotrophic mutant 
Salmonellae would then lyse within the phagosome (2), or escape from the vesicle 
into the cytoplasm (4), before disintegrating (5). Either way, the plasmids would be 
liberated and imported into the A P C nucleus (3). With subsequent host cell 
expression, the foreign proteins can be processed and presented in the context of 
















mononuclear cells (PBMCs), and infected with bacteria. In order to gauge optimal 
timing of infection, cell cultures were surveyed and manipulated at different time-
points (day 6-day 8 post-isolation of PBMCs). It was thereby determined that 
macrophages (as adherent cells) are most numerous on day 8. Moreover, using 
Salmonella bearing prokaryotic vectors encoding GFP, as many as seven bacteria at 
once could be fluoroscopically visualized within a single cell following infection at a 
multiplicity of 100 (not shown). 
Using the basic protocol described (see Chapter II), macrophages were 
infected with the various Salmonellae, then co-incubated with x-gal, the 8-
galactosidase substrate, at different time-points. Based on the degree of staining that 
resulted, it was determined that a delay of 36-48 hours post-infection yields the most 
extensive reporter gene expression. 
Ultimately, we arrived at an effective, precise protocol with which to evaluate 
our first hypothesis (Figure 2). To further refine infectious conditions, we varied 
multiplicity of infection (MOI), and found manifest evidence of an infectious dose-
dependency: More /3-galactosidase activity is seen in cultures infected at higher MOI, 
with (MOI=100)>(MOI=50)>(MOI=25)>(MOI=1). At the highest MOI tested (100), 
the degree of x-gal staining suggested -50% of macrophage expression of the reporter 
gene. 
Overall staining patterns are described in Table 2. Negative controls included 
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Figure 2 The original infectious protocol AroA- Salmonella was transformed 
using electroporation with one of two plasmids encoding 8-galactosidase as shown. 
Control bacteria were either left untransformed or transformed with irrelevant 
("pX") plasmids. Macrophages were cultivated from human peripheral blood 
mononuclear cells (PBMCs) using the adhesion method, then infected at M O I shown 
on day 8 post-isolation. Following infection, cells were washed with gentamicin-
containing medium. Because at this time we were using a tetracycline-sensitive 
strain (33275), we also added this antibiotic to ensure intracellular bacterial death. 
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uninfected macrophages, cells infected with untransformed bacteria and cells infected 
with bacteria harboring irrelevant plasmids. In the presence of x-gal, these cultures 
showed no blue staining at all (Figure 3A). 
Macrophages infected with bacteria bearing the pTrc-/3 vector, on the other 
hand, did show some, albeit minimal, staining in the presence of the reporter gene 
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substrate. The intracellular morphology, however, was distinctive: These cells bore a 
scattered, punctate pattern, suggestive of vacuolized, contained bacteria that are 
actively expressing the /3-galactosidase vector themselves (Figures 4A and 4B). 
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In contrast, cells infected with Salmonellae carrying the pSLICK-z vector 
stained in a diffusely intracellular way, suggesting that the macrophages are 
expressing the reporter gene themselves (Figures 3B, 5A and 5B). 
In light of these staining patterns, we concluded that it was indeed possible to 
employ attenuated S. typhimurium as a plasmid-delivery vehicle. The results of this 
initial reporter gene study support the proposition that extra-genomic DNA can be 
transferred from an invasive bacterium to its target cell, which goes on to express the 
foreign vector itself. 
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Figures 3-5 Salmonella can be used to transduce human macrophages in vitro 
such that they express a reporter gene Macrophages were infected with aroA-
Salmonella (33275) at MOI—100. Figure 3A shows cells infected with bacteria 
carrying irrelevant plasmids, which yielded no visible blue staining. Figure 3B, on 
the other hand, represents cells infected with pSLICK-z, which encodes 8-
galactosidase under the control of a eukaryotic promoter. Note multiple diffusely 
blue macrophages. Figures 4A and 4B show cells infected with Salmonellae bearing 
pTrc-8, which contains 8-galactosidase under a prokaryotic promoter. Minimal, 
punctuate blue staining is evident, probably reflecting phagocytosed bacteria. 
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F i g u r e 5 B 
Attenuated Salmonella can deliver a viral gene vector to human macrophages: 
eukaryotic expression of SIV env detected by RT-PCR 
With the vision of a vaccine delivery system in mind, we next chose to 
evaluate the system using a viral gene instead of a reporter gene. Furthermore, we 
undertook to confirm conceptual design at the level of transcription, instead of 
translation. 
Therefore, once again we carefully chose our experimental vectors, including 
one encoding the env gene of SFVmac239 (pCDNA3.1/SIVe«v). Primers were designed 
towards recovery of the env gene transcript (See Chapter II for details). Again, we 
transformed aroA- bacteria (33275) and cultivated primary human macrophages from 
PBMCs. 
After a sufficient period of time post-infection (36-48 hours, as determined 
earlier), macrophages were scraped to liberate them from the culture dish, then pooled 
and lysed. RNA was extracted from the cell lysates in a process involving the 
addition of DNase. Finally, RT-PCR was carried out to recover any viral gene 
transcripts (Figure 6). 
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Figure 6 The infectious protocol used towards RT-PCR Salmonella was 
transformed with a eukaryotic vector encoding SIVenv as shown. Macrophages were 
infected on day 8 following isolation of human PBMCs. Controls for this experiment 
included uninfected macrophages, macrophages infected with bacteria carrying 
irrelevant plasmids, and macrophages to which nakedpCDNA3.1/SIVenv was added. 
Approximately 40 hours post-infection and washing, the cells were harvested, pooled 
and lysed. RNA extraction included a DNase step. RT-PCR employed primers 
specific for SIVenv. 
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uninfected macrophages, macrophages infected with untransformed bacteria and 
macrophages infected with bacteria carrying irrelevant plasmids (including 8-
galactosidase vectors). Additionally, sham "pellets" comprising pure D N A were used 
as a control for the DNase treatment. PCR with the env primers yielded a product of 
the appropriate size (1500bp) only from the cells infected with Salmonellae harboring 
pCDNA3.1 /SIVenv (Figure 7). 
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Thus, we believe that we confirmed the efficacy of our plasmid-delivery 
system at the level of transcription. Recovery of the m R N A transcript of SIVenv 
from infected macrophages suggests that the attenuated bacteria were able to deliver 
the plasmid to their target cells in such a way as to permit the latter to express the 
viral gene. 
Figure 7 Salmonella can be used to transduce macrophages in vitro such that 
they express a viral gene RT-PCR using primers specific for SIVenv performed on 
RNA extracted from cell lysates yielded the following results: (A) macrophages 
infected with bacteria carryingpCDNA3.1/SIVenv, (B) macrophages infected with 
bacteria carrying pSLICK, (C) macrophages infected with bacteria carrying pSLICK-
z, (D) macrophages infected with untransformed bacteria, (E) uninfected 
macrophages, (F) reagent control, and (G) lOObp ladder. Note that only in lane (A) 
do we see a band corresponding to the size of SIV env. Not shown are results of the 
same RT-PCR done on sham D N A "pellets " comprising 0.01 ng, 0.1 \ig and l.Oyg of 
p C D N A3.1/SIVenv, which yielded no bands. 
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Attenuated Salmonella can deliver a viral gene vector to human macrophages: 
eukaryotic expression of HIV-1 env detected by immunocytochemistry 
We continued studying our system of targeted plasmid delivery using viral 
vectors. In an attempt to once again prove efficacy at the level of translation, we 
undertook to detect expression of a viral protein using immunocytochemistry. We 
therefore transformed aroA- Salmonella with a eukaryotic promoter-driven 
expression vector that encodes the HIV-1 genes tat, rev and env 
(pCDNAl.l/HIVtof/'evenv). At this time, however, we used a different auxotrophic 
Salmonella strain (14028), which is reportedly more invasive than 33275. Human 
macrophages were cultivated in the usual manner, then infected in a protocol based 
on our previous experience (Figure 8). Macrophages were fixed and blocked before 
staining using a Vectastain® alkaline phosphatase (AP)-based kit (See Chapter II for 
details). 
Overall results of the staining are listed in Table 4. Initially, a horseradish 
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Figure 8 The protocol used to infect human macrophages toward 
immunocytochemistry Human macrophages were infected in vitro as usual, as 
shown. Approximately 40 hours post-infection and washing, macrophages were fixed 
and blocked in their wells. Serum from an individual infected with HIV-1 subtype C 
was used for primary antibody in order to be specific for the viral source of the gene 
encoded by the vector carried by the bacteria. Secondary antibody conjugated to 
alkaline phosphatase (AP) was added, then the cells were incubated with an A P 
substrate for development. 
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peroxidase (HRP)-based system was used, but endogenous peroxidase activity within 
the macrophages proved difficult to fully neutralize, yielding muddy-appearing 
negative control cultures (not shown). Using AP instead, however, permitted very 
"clean" staining, with no visible background in the control cultures (Figures 9-11). 
Macrophages infected with Salmonellae bearing pCDNALl/HIVta^evenv 
demonstrated widespread staining, a pattern consistent with the more invasive strain 
(14028) and the high MOI (100) used in this experiment (Figures 9-11). Also visible 
among the red-colored macrophages were two persistently colorless types of cells: T-
cells (which appeared as smaller, more rounded non-adherent cells) and residual 
bacteria (which account for much of the apparent debris in the surrounding medium). 
These populations, therefore, functioned as an additional, internal control for the 
study. 
Attenuated Salmonella can deliver a viral gene vector to human macrophages: 
eukaryotic expression of the HIV tat splice product detected by RT-PCR 
Our next challenge was to confirm, unequivocally, that what we had detected 
thus far was evidence of eukaryotic, not prokaryotic, expression. Could the 
immunocytochemical staining, for example, simply reflect bacterially-expressed 
protein that had permeated the macrophage cytosol? Were the bacteria themselves 
actually capable of driving a CMV promoter through the use of a cryptic prokaryotic 
41 
Figures 9-11 Salmonella can be used to transduce human macrophages in vitro 
such that they express a viral gene Macrophages were infected with aroA-
Salmonella (14028) at MOI=100. The images represent cells infected with either 
untransformed bacteria (Figures 9A, 10A and 11 A) or Salmonella carrying 
pCDNAl. 1VHIVtatrevenv, which encodes the viral genes under the control of a C M V 
promoter (Figures 9B, 10B and IIB). Immunocytochemical staining for HIV Env 
reveals widespread color, suggesting effective receipt and expression of 
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enhancer, for example (48-53)? Although the /3-galactosidase vectors we used in our 
original study, pTrc-/3 and pSLICK-z, appeared specific for prokaryotic or eukaryotic 
usage, respectively, we ultimately discovered that a CMV promoter can in fact be 
used by Salmonella in the context of certain plasmid backbones (e.g., many 
Invitrogen® vectors). A culture of Salmonella transformed to carry a vector (pVAXl) 
encoding HIV-1 gag, for example, tests positively for p24 content by ELISA (data 
not shown). 
We sought, then, to prove the conceptual premise of our system by detecting 
evidence of RNA splicing, a uniquely eukaryotic phenomenon (54, 55). Initially, we 
took advantage of a HeLa cell-derived multinuclear-activation-of-a-galactosidase-
indicator (MAGI) assay (56), which allows us to gauge the presence of HIV-1 Tat by 
measuring /3-galactosidase activity as a surrogate marker. Though the assay worked 
to our satisfaction (not shown), we later learned that the gene product of the first tat 
exon alone is sufficient to function as a trans activator (57). 
We then instead turned to PCR once again. Primers were carefully designed 
to flank HIV tat (Figure 12). After infecting human macrophage cultures as before 
(e.g., Figure 8) with Salmonella bearing pCDNAl.l/HIWafr-evenv, the cells were 
liberated, pooled and lysed (See Figure 6). RT-PCR was carried out after extraction 
of mRNA (as explained in Chapter II). Controls included macrophages to which pure 
pCDNALl/HIVta-'revenv was added. Results are listed in Table 5 and illustrated 
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Our PCR products were limited to the gel lane corresponding to the lysate of 
macrophages infected with Salmonella carrying pCDNAl. l/HFV7a//-eve«v. W e 
therefore believe that the brightest band represents spliced tat, which can only be a 
consequence of macrophage expression. Thus, we again have confirmation of the 
intended design, wherein attenuated Salmonellae serve as vehicles for delivery of 
eukaryotic vectors to their macrophage targets. 
DISCUSSION 
Using bacteria as D N A delivery vehicles for genetic immunization was first 
attempted by Jerald Sadoff s team (58, 59). Attenuated Shigella was employed to 
deliver a reporter gene vector in vitro to cultured B H K cells, and also generated in 
vivo lymphoproliferative responses specific for the same foreign antigen when 
administered intranasally to mice. Another group soon followed suit (46), exploring 
the possibility of using Salmonella as an orally-administered inoculation bearing 
vectors encoding two virulence factors of Listeria. Again, both direct evidence of 
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Figure 13 Salmonella can be used to transduce human macrophages in vitro 
such that they express a viral gene RT-PCR using primers designed to recover 
spliced HIV-1 tat performed on RNA extracts from cell lysates yielded the following 
results: (A) WObp ladder, (B) reagent control, (C) macrophages infected with 
Salmonella bearingpCDNAl. 1 /HIVtatrevenv, (D) uninfected cells, and (E) 
macrophages with pure pCDNAl. 1/HIVtatrevenv added. Note that the brightest band 
in lane (C) corresponds to a size equivalent to that of full tat (both exons together). 
Recovery of a splice product confirms eukaryotic (and not prokaryotic) expression. 
genetic transfer to host cells (peritoneal macrophages) as well as systemic immune 
responses were documented. 
Thus, when we began our investigation, there was a small but sufficiently 
promising precedent. As we undertook our own studies, several other groups 
continued to pursue the burgeoning model of bacteria as plasmid-delivery vehicles in 
vaccine design (60-68). All relevant studies published to date, however, have 
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involved either cell lines or murine cells (in vitro or in vivo); our experimentation is 
unique in demonstrating the efficacy of the system in primary human cells. 
Designing such a system notwithstanding, we are confronted with the question 
of its potential utility as a successful vaccine strategy. Are macrophages, for 
example, truly the most desirable target cell for our purposes? 
Before the primacy of dendritic cells (DCs) was recognized, macrophages 
were understood to be important as antigen-presenting cells (APCs) (69). At the very 
least, they were known to be capable of expressing MHC class II glycoproteins on 
their surface, processing endocytosed antigen and producing IL-1. 
While we now appreciate that DCs are the most important APCs (especially 
given their role in priming naive T-cells), we nonetheless must accept the 
complementary role in presentation played by macrophages. They are, for example, 
specialized in the phagocytosis of large particles, including antigens from bacteria 
and parasites, whether intracellular or extracellular pathogens. Indeed, their 
phagocytotic capacity is a first-line defense, and they are important in mediating 
innate immune responses (70). 
More important towards our end, however, is their contribution to the effector 
phase of adaptive immunity. The ingestion of microorganisms, though a primitive, 
non-specific defense, also induces the expression of MHC class II and co-stimulatory 
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(e.g., B7) molecules. Furthermore, macrophages also produce cytokines that 
stimulate T-cell proliferation and differentiation (e.g., IL-12). In fact, the principal 
function of macrophages is ultimately the generation of CD4+ effector T-cells (71). 
Activated macrophages also become more efficient APCs, with increased cytokine 
production and expression of MHC class JH and co-stimulatory molecules. 
Additionally, there is a positive feedback process, by which activated T helper cells 
produce interferon (IFN)-7 and CD40L, which, in turn, induce MHC class II and co-
stimulatory molecules (71). 
Thus, although macrophages are not necessarily our first choice as vaccine 
targets, they are not without relevance or utility in the current context. A more 
challenging issue, then, is the well-documented observation that Salmonella invasion 
of macrophages induces apoptosis. What if our vaccine kills the very APCs it 
targets? 
Of the many studies that have characterized and explored Salmonella-induced 
cell death, the vast majority (72-82) exclusively involve murine macrophages or cell 
lines, while only three related studies (83-85) included human cells to any extent. 
Moreover, some have noted directly that S. typhimurium entry into murine 
macrophages ". .. causes considerably more eukaryotic cell death than does entry of 
the same Salmonella serovar into human macrophage cells" (86). This finding is 
consistent with our own work: Despite reports of murine macrophage death 
occurring within minutes of Salmonella invasion (72), we routinely surveyed our 
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human cells with trypan blue 36-48 hours post-infection, and found that < 5 % of cells 
were dead. One possible explanation for this apparent discrepancy is the difference 
across species in host resistance factors. Specifically, in the case of susceptibility to 
Salmonella virulence, it has become clear that genes mapping to the Bcg/Ity locus are 
important (87-95). There are, however, differences between mice and humans with 
respect to the encoded protein that has been identified, natural resistance-associated 
membrane protein (NRAMP) (89). Indeed, the Bcg/Ity locus displays considerable 
polymorphism, even within a species, yielding corresponding phenotypic variation in 
NRAMP. Even functional variability according to the sex of the host has been 
observed, suggesting a role for hormonal influences (91). The contribution of loci 
other than Bcg/Ity has yet to be fully elucidated (93). Importantly, however, it is 
known that the protein product of the mammalian suppressor of svgl (mssl) gene 
corresponds to the ATPase part of the 26S protease complex, which is believed to 
have a pivotal role in regulating apoptosis. The fact that human macrophages display 
a greater degree of mssl expression than murine macrophages (86) is further 
consistent with our observations regarding the relative resilience of human cells to 
Salmonella invasion. 
Another factor to consider in a discussion of the possibility of macrophage 
apoptosis is bacterial strain choice. At least one recent study documents the 
substantial variability across Salmonella serovars in their cytotoxicity in human 
macrophages, including the extent of apoptosis induced (96). 
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The case for permitting a Salmonella-based vaccine to be invasively delivered 
to macrophages is strengthened by one final consideration: the potential for cross-
presentation by DCs. While a more detailed discussion of DCs in the context of this 
system is forthcoming (See Chapters IV and V), it should be noted here that antigen 
from apoptotic cells can be acquired by bystander DCs and cross-presented to T-cells 
(97-100). In fact, Mary Jo Wick and colleagues specifically confirmed this process 
using murine macrophages rendered apoptotic by Salmonella (78). Thus, it may 
ultimately emerge that our method of Salmonella-facilitated genetic immunization is 
particularly effective in vivo because of an unintended toxicity to macrophage targets. 
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Chapter IV: 
Infection of dendritic cells with Salmonella typhimurium induces 
maturation but is also cytotoxic 
INTRODUCTION 
The importance of mucosal immunogenicity in vaccine design has long been 
recognized (101, 102), especially in the case of combating HIV infection and disease 
(103-105). Mucosal surfaces are the primary sites of transmission for most infectious 
diseases, and over 75% of all HIV transmission, in particular, occurs by the mucosal 
route (105). If we can induce mucosal immunity with vaccination, we may be able to 
prevent pathogen entry altogether. 
Using S. typhimurium to deliver a vaccine would permit mucosal involvement 
at the outset: Inoculation itself would be mucosal, through the oral route into the 
digestive tract. Furthermore, the bacteria are known to egress from the gut lumen via 
the M cells, which overlie Peyer's patches (106). Once these specialized epithelial 
cells are effectively traversed (through transcytosis), Salmonellae reach a large 
intraepithelial "pocket" containing T lymphocytes, B lymphocytes and macrophages. 
Below the epithelium, the bacteria reach DCs (106-108). Because of this convenient 
natural route of administration and targeted entry, live attenuated Salmonella has 
previously been proposed as a paradigm of mucosal vaccines (109). In fact, some 
have called specifically for vaccines targeting M cells (109-111), and at least one 
group has proceeded with an in vivo investigation of such a scheme using reovirus 
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vectors (112). Indeed, in order to fully and accurately evaluate the potential for 
mucosal as well as systemic immunogenicity, we must perform in vivo studies. 
RESULTS 
Taking advantage of the OY4/OT mouse model: an attempt to take the system 
in vivo 
We were interested in exploring the potential strength of our vaccine delivery 
system in vivo. Specifically, we hoped to take advantage of so-called "OT I" and 
"OT II" mice, which are transgenic for T-cell receptors specific for ovalbumin (OVA) 
epitopes in the context of MHC class I and II restriction, respectively (113, 114). We 
felt that the murine model would not only enable us to assess the efficacy of oral 
inoculation, but also to examine the extent to which DCs are successfully targeted by 
the transformed bacteria. 
We therefore began by constructing a plasmid vector encoding OVA under 
the control of a eukaryotic promoter. After sequencing the vector and confirming its 
expressive capacity, we transformed aroA- Salmonella (14028) with it, as before. 
Next, we designed three different protocols involving OT mice and the new 
OVA vector delivery vehicles. The first of these (Figure 14) was intended simply to 
confirm DC maturation and T-cell proliferation following in vitro co-culture. Later 
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(Figure 15), we planned to actually inoculate our animals, and ultimately to look for 
more specific T-cell responses (Figure 16). 
Thus, we began by cultivating murine bone marrow-derived DCs (BMDCs) in 
vitro. Based in part on our protocol for infecting human macrophages (See Chapter 
III), we similarly undertook to infect BMDCs with Salmonella using varying MOI 
(10-100). 
Our plans for further manipulation of the cells were truncated, however, when 
we observed severe cytotoxicity, apparently as a direct consequence of exposure to 
the bacteria. Staining with trypan blue, for example, revealed almost wholesale death 
of the murine BMDCs (not shown), even at low MOI. Indeed, we are not the first to 
observe such toxicity in DCs: Yrlid et al. (115) saw similar rates of Salmonella-
induced apoptosis of murine BMDCs, specifically when using the same strain 
(14028) that we used to infect the cells. Additionally, others have found Salmonella 
exposure to be toxic even to human DCs (116), apparently because of a virulence 
factor encoded by the bacterial sipB gene, which activates caspase-1 towards 
apoptosis (117). Rescigno and Borrow have therefore proposed, in fact, that such 
cytotoxicity may serve teleologically as a mechanism of immune evasion (118). 
We found nonetheless that, 24 hours after infection at MOI=10, we were able 
to assay some surviving BMDCs for maturation markers, as planned. What cells 
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Figures 14-16 An attempt to take the system in vivo Figures 14-16 illustrate 
schematically our original plans to take advantage of the transgenic "OT" mouse 
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remained viable after bacterial infection, therefore, were stained for CD40, M H C 
class II and CD86. Flow cytometry data reveal that the Salmonella-exposed DCs did, 
in fact, mature. Moreover, they express relevant surface markers to a greater extent 
than DCs incubated with LPS as a positive control (Figure 17). This finding, too, is 
consistent with the observations of others (119, 120). Whether LPS-induced 
maturation occurs through the use of toll-like receptors (TLRs) (121, 122) or not 
(123, 124), it appears that Salmonella-induced NF/cB activation is more pronounced 
than that by LPS alone (125). 
Designing a vaccination trial to detect mucosal as well as systemic responses: 
another attempt to take the system in vivo 
Despite our initial frustrations with the murine model, we persisted in hoping 
to achieve in vivo success with our DNA vaccine delivery system. Although we had 
observed evidence of substantial cytotoxicity on exposure of murine DCs to 
Salmonella in vitro, we hypothesized that there would be a greater chance of 
efficacious antigen presentation in vivo. Not only would the functional MOI be lower 
with indirect, oral administration, we would also likely benefit from the phenomenon 
of bystander DC presentation (78, 97-100). Furthermore, we were inspired by a 
number of publications documenting successful immunogenicity with Salmonella 
inoculation of mice (46, 60, 63, 65, 66, 126, 127), despite presumed toxicity towards 
DCs. 
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Figure 17 Infection of murine bone marrow-derived dendritic cells (BMDCs) 
with S. typhimurium induces maturation Infection of B M D C s with Salmonella (at 
MOI=10) is seen to increase expression of relevant surface molecules. LPS was also 
added to a pool of uninfected cells as a positive control. Note that bacterial infection 
seems to yield a greater degree of maturation than LPS, as reflected in the relative 
degrees of expression of the maturation markers (CD-40, MHC-II and CD-86) 
detected in this study. "Salm/pVAXl " refers to DCs infected with bacteria harboring 
"empty "pVAXl vector; "Salm/pOVA " refers to DCs infected with bacteria carrying 
pVAXl-ova. Not shown are the results of staining uninfected, unmanipulated B M D C s 
with the same antibodies as a negative control, which demonstrated minimal 
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At a later date, we therefore proceeded to design and carry out an in vivo trial 
involving naive BALB/c mice, which was the species available to us at this time 
(Figure 18). The plasmid vector with which we transformed our bacteria in this case 
encodes both HIV-1 env and gag under dual eukaryotic promoters. Mice were orally 
vaccinated three times over the course of 6 weeks using inocula of varying sizes. The 
group of mice serving as positive control was vaccinated with the same DNA vaccine 
vector intramuscularly, an approach already known to yield systemic humoral and 
cellular responses (128). Finally, both blood and feces were harvested for eventual 
ELISA, while splenocytes, mesenteric lymph nodes (MLNs) and Peyer's patches 
(PPs) were harvested for ELISpot assays. Once again, however, our efforts were 
limited by confounding circumstances: MLN cells proved too contaminated (by 
adipose tissue) to assay, and PP cells were too few. Splenocytes, on the other hand, 
were intact and usable but yielded no evidence of systemic immunity in response to 
Env or Gag re-stimulation in vitro. Similarly, humoral responses were seen by 
ELISA to be minimal or nil. 
We were thus prompted to consider the basis for this apparent vaccination 
failure. Was there, for example, still too much APC death with the Salmonella doses 
we used? Additionally, we speculated about the possibility of tolerogenesis instead 
of immunogenesis: The gut, after all, is evolved for tolerance, and the mucosal 
immune system mounts tolerogenic responses most often, as it receives the myriad 
antigens associated with microbial flora or proteins in the food stream (31, 101, 129, 
130). DCs are known to play a role in the mediation of tolerance (131, 132), and are 
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Figures 18 and 19 A second attempt to take the system in vivo Two brief trials 
were designed wherein transformed bacteria were administered orally (PO) to 
BALB/c mice. Control groups received the vaccine vectors as naked D N A given 
intramuscularly (IM) (Figure 18) or carried by Salmonella given intraperitoneally 
(IP) (Figure 19). Doses were given as indicated, and the mice were sacrificed to 
permit tissue harvesting. Additionally, blood and feces were harvested during the 
course of the first trial (Figure 18). 
60 








p env-gag IM (100^g) 
Sa/m/pVAX1 P O ( 1 x1010) 
Salm/penv-gag P O (1 x 1010) 
Salm/penv-gag P O (1 x 109) 
Salm/penv-gag P O (1 x 108) 
Salm/penv-gag P O (1 x 107) 
unvaccinated 
Plan: 3 doses, 3 w e e k s apart 
blood, feces - E L I S A for A b (IgG/A) 
spleen, G A L T - ELISpot for C M I 
Week 
F i g u r e 1 8 
(Harvest blood and feces for A b ) 








S a l m i p g a g P O (1 x109) 
Salmlpgag P O (1 x 107) 
Salmlpgag P O (1 x105) 
Salmlpgag P O (1 x103) 
Salmlpgag IP (1 x 107) 
Salmlpgag IP (1 x 103) 
unvaccinated 
Plan: 
F i g u r e 1 9 
1 dose, sacrifice after 2 w e e k s 
spleen, G A L T - ELISpot for C M I 
14 days 
also known to be anatomically associated with both M L N s (133) and PPs (134). It 
would seem, however, that by virtue of their induction of DC maturation, our vaccine 
vehicles could eschew tolerogenesis (135, 136). 
We proceeded by attempting a second, shorter in vivo trial involving a lower 
dose range and a simpler vector (encoding only HIV-1 gag). Additionally, we 
included a new group of mice that were inoculated via the intraperitoneal (IP) route 
(Figure 19). We were also sure to process our MLNs cleanly this time, by using a 
lymphocyte-separation medium formulated especially for murine cells. 
Results of IFN-y ELISpot assays revealed no spot-forming cells (SFC) from 
PPs, and only a moderate response (100 SFC/106 cells) from splenocytes in the group 
that had received the highest oral dose (IO9 bacteria). More significantly, the group 
that was vaccinated with the highest IP dose (107 bacteria) yielded -300 SFC/106 
from cells of the MLNs. 
Thus, we see evidence of the system's efficacy in vivo only perhaps when the 
bacteria are delivered directly to APCs - in this case, within the peritoneum. 
Peritoneal macrophages, however, are known to be weak APCs (137), although they 
do produce a soluble factor that enhances the antigen-presenting capacity of DCs 
(138). While some groups have found that murine peritoneal macrophages do have 
the ability to prime T-cells (139-141), it may be more likely that DCs derived from 
peritoneal precursors did the effective presenting (142-145). 
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The weakness or absence of a response with oral administration, however, 
merits further consideration. One possible explanation is our Salmonella strain 
choice. - Is it so much more toxic than the various other strains used in effective 
murine trials (46, 60, 63, 65, 66, 68, 126, 127, 146)? One group, after all, used our 
strain (14028) specifically when apoptosis of murine APCs was the desired outcome 
(78). Similarly, different Salmonella strains may display distinct physiologic 
dynamics with respect to exiting the gut and reaching relevant lymphoid tissue. Thus, 
the timing of our sample harvesting and immunological assaying may have been sub-
optimal (147). 
Salmonella infection of human dendritic cells induces maturation 
Because of the unique importance of DCs as priming APCs, we wanted to 
further confirm the ability of our Salmonella-based vaccine delivery system to reach 
and activate these cells. Rather than continue to use murine tissue, however, it was 
sensible instead to return to human cells. 
We therefore undertook to isolate human PBMCs and cultivate DCs in vitro 
(See Chapter II for protocol details). Infection of the immature cells with Salmonella 
was carried out in a manner similar to that of our previous protocol involving 
macrophages (Figure 20). Although we saw considerably less cytotoxicity on 
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exposure to Salmonella than with murine DCs, we did appreciate a greater level of 
cell death relative to human macrophages infected with the same bacteria at the same 
MOI (not shown). 
Approximately 36 hours post-infection, the DCs were pooled and stained for 
maturation markers. Flow cytometry results of the initial assay are shown in Table 6. 
M E A N V A L U E S 
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Later, we also stained for DC-LAMP, with LPS added to one pool of cells as a 
positive control (Figure 21). 
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Figure 20 Infection of human dendritic cells (DCs) with S. typhimurium 
induces maturation Human PBMCs were isolated, then subjected to CD14+ 
selection. A week-long cultivation of these cells in the presence of GM-CSF and IL-4 
yielded immature DCs. Infection with Salmonella was performed at a lower M O I 
than macrophages (25), and washing was done carefully, so as not to lose these non-
adherent cells. 
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W e see, therefore, that Salmonella infection of human DCs results in 
increased expression of molecules associated with DC maturity. Furthermore, in the 
context of vaccine design, DC maturation is a wholly desirable effect (135). Our 
observation that Salmonella induces efficient human DC maturation is consistent with 
the findings of other groups (119, 120, 135, 148). It should also be noted that, as a 
potential tool of vaccination, Salmonella compares favorably in this regard with other 
microbes, which have apparently evolved instead to interfere with DC maturation 
(118). 
In addition to the up-regulation of known maturation markers, it has been 
observed that Salmonella infection of DCs also generally activates them, resulting in 
part in the production of chemokines that work to recruit macrophages, neutrophils, 
natural killer cells and other DCs (119, 149). At the level of activation of members of 
the NF/cB family, in fact, Salmonella is seen to activate DCs better than pure LPS 
(125). Cytokines secreted by DCs as a consequence of Salnonella exposure include 
TNF-a, IL-12, IL-6 and IL-18 (116, 117, 150, 151). 
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Figure 21 Infection of human DCs with S. typhimurium induces maturation 
Cells were stained with either an isotype control or antibodies against the maturation 
markers listed. Note that CD83 is a surface marker, while DC-LAMP requires that 
the cells be permeabilized. Control cells received the additional known maturation 
stimulus of pure LPS. Not shown here are similar flow images reflecting enhanced 











































While immature DCs are specialized in capturing and processing antigens into 
peptides towards MHC presentation, mature DCs are initiators and modulators of the 
immune system (131, 152). Indeed, the maturation of DCs is a crucial step in the 
generation of an immune response. 
The nature of possible interactions between DCs and Salmonella, therefore, is 
an important consideration for us. Will the attenuated bacteria be a hindrance or a 
help in our attempt to deliver DNA vaccines to APCs? Will Salmonella effectively 
target DCs in vivol Will DCs survive their encounter with the bacteria, at least long 
enough to present to, and prime, T-cells? And will our plasmid-delivery vehicles 
themselves trigger maturation of DCs, thereby ensuring an APC that is ready for 
immunogenesis? 
Although macrophages were long regarded as the main target of Salmonella, it 
is now known that the bacteria are first internalized by DCs. In fact, one study 
suggests that DCs actually represent more receptive host cells than macrophages 
(153). Furthermore, in addition to the induction of maturation and general activation 
described herein, bacteria are seen to induce the neo-biosynthesis, stabilization and 
surface expression of MHC molecules in DCs (148). Thus, evidence suggests that 
Salmonella would likely target and interact with DCs in a manner appropriate for 
vaccine delivery. 
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It has recently been observed by one group that encounters between 
Salmonella and monocytic precursors in the skin prevent differentiation into DCs 
(154). Nonetheless, the same investigators have found that encounters between the 
bacteria and differentiated DCs yield an effective immune response towards antigens 
expressed by the Salmonella (155). Furthermore, LPS and inflammatory cytokines 
associated with Salmonella infection are known to stimulate the mobilization of 
tissue-based DCs from the periphery to secondary lymphoid organs (156, 157). Thus, 
although Salmonella will not encourage the conversion of monocytes to dendritic 
cells, it is very likely that they will encounter existent dendritic cells in the course of 
infection (as with any microbe) or inoculation. 
Interestingly, Svensson et al. note that the increased surface expression of 
MHC-I, MHC-II, CD86, CD40 and CD54 that they observe on DC encounter with 
Salmonella does not require bacterial viability or internalization (120). Thus, it may 
be speculated that bacterially induced maturation and activation on this level is purely 
a function of LPS exposure, and would therefore likely be a matter of TLR signaling 
(121, 122, 124). In this way, bacteria can be considered to harbor and deliver a built-
in vaccine adjuvant (158). 
On the other hand, the same group also notes that the up-regulation of CD80 
expression does in fact require viable, invasive bacteria and internalization (120). 
Thus the mechanism of such up-regulation associated with the maturation process is 
unclear. It can be speculated, however, that the bacterially induced release of 
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cytokines such as TNF-o; works in a positive feedback manner to encourage 
maturation. 
If we are to undertake to use Salmonella to deliver vaccines to DCs then, we 
must also concern ourselves with the potential effects that bacterial virulence factors 
would have on their targets. The possible induction of apoptosis has been established 
(vide infra), although we may perhaps avoid this fate by choosing our strain carefully. 
But what of mechanisms the bacteria have evolved towards escaping immune 
surveillance as they persist within their host cells? Expression of many of the 
relevant virulence proteins are under the control of the transcription regulator PhoP. 
Studies show, however, that PhoP has no bearing on the ability of DCs to internalize 
Salmonella, or to go on to process and present antigens (153). Moreover, PhoP does 
not affect the maturation process induced in immature DCs that encounter S. 
typhimurium, specifically (120). Thus, it is unlikely that Salmonella virulence factors 
would interfere with the use of the bacteria in targeted vaccine delivery. 
Hence we see that interaction with Salmonella stimulates DCs to mature, a 
critical step towards becoming activators and regulators of T-cells. Such an effect is 
precisely what is required of a vaccination tool. 
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Chapter V : 
Human dendritic cells can be transduced in vitro using attenuated 
Salmonella typhimurium 
I N T R O D U C T I O N 
As the most potent and effective APCs known, DCs should be a central 
concern in vaccinology. They alone initiate immune responses by stimulating 
quiescent, naive and memory T lymphocytes. Indeed, they serve as a unique liaison 
between antigen and T-cell; antigens that have no contact with DCs are ignored by 
T-cells (159). Furthermore, DCs are the sentinels in immune surveillance and can 
migrate when necessary to optimize clonal selection. Moreover, in addition to 
activating lymphocytes, they also work to tolerize T-cells to self-anti gens. Thus, DCs 
can be a powerful tool for manipulating the immune system (131), and the potential 
for targeting DCs should be a major consideration in vaccine design. 
Since the singular significance of DCs was recognized, in fact, many groups 
have indeed undertaken to target, or otherwise involve, DCs in their immunization 
strategies. Against infectious pathogens, in particular, DCs have been specifically 
targeted with adenovirus-based vectors (160-162), recombinant yeast vectors (163), 
liposome-encapsulated proteins (164), pseudo-typed virus (165) and synthetic peptide 
immunogens (166). DCs have also been effectively reached by DNA vaccines (167-
169), including in the skin through the use of a topical adjuvant (170). Linking 
vaccines to Fms-like tyrosine kinase receptor-3 ligand (Flt-3L) (171) or to the 
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lysosomal-associated membrane protein 1 (LAMP1) targeting sequence (172) has 
also resulted in successful DC contact. 
After designing our system of facilitated DNA vaccine delivery in the context 
of human macrophages, we went on to demonstrate that our aroA- bacteria can infect 
and mature human DCs. We were therefore inspired to continue working with human 
DCs, in order to verify that the strategy itself can be used to target these all-important 
cells. We were encouraged, too, by the work of other groups, who had successfully 
reached DCs with bacterially-based systems (60, 68, 127, 173-177). 
R E S U L T S 
Attenuated Salmonella can deliver a reporter gene vector to human dendritic 
cells: eukaryotic expression of/3-galactosidase detected by incubation with 
substrates and flow cytometry 
. We were interested in reproducing some of our early macrophage studies, this 
time in the context of primary human DCs. We therefore once again chose to work 
with reporter gene vectors in order to demonstrate manifestly that attenuated 
Salmonella can be used to deliver functional plasmids to target cells. 
We began then by isolating human PBMCs, then cultivating DCs in vitro, as 
before (See Chapter II for procedural details). Using a protocol based on our 
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infection of macrophages, we infected immature DCs with aroA- S. typhimurium 
(33275) bearing either pTrc-/3 or pSLICK-z (Figure 22). After 1 hour of exposure to 
the bacteria, careful washing with antibiotic-containing medium and overnight 
incubation, the /3-galactosidase substrate, x-gal, was added to the wells (See Chapter 
II for precise protocol). Overall results of the staining are listed in Table 7. 
D E N D R I T I C C E L L S /3-GALACTOSIDASE S T A I N I N G 
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As with macrophages that were infected with these same bacteria, the 
difference in staining morphology is clear: Cells infected with Salmonella carrying 
the prokaryotic vector show a spottiness suggestive of contained bacteria that are 
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Figure 22 Salmonella can be used to transduce human DCs in vitro such that 
they express a reporter gene AroA- S. typhimurium (33275) bearing different 8-
galactosidase vectors, as shown, were used to infect immature human DCs 
(M0I=25). Approximately 40 hours post-infection, the cells were fixed, then 
incubated with x-gal, a 8-galactosidase substrate. 
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expressing the reporter gene themselves, while DCs infected with bacteria harboring 
the eukaryotic vector stain diffusely, apparently throughout the cytosol (Figures 23-
25). At higher magnification, a mature DC phenotype is grossly evident (Figure 25). 
As before, when we varied MOI, we appreciated a dose-dependency reflected 
in the relative number of cells staining blue per well (not shown). Staining 36-48 
hours after infection, for example, we saw very few blue cells per field under low 
magnification with MOI=5 (0-4), in contrast to the number of blue cells per field with 
MOI=50 (60-70). We found, however, that human DCs (not unlike murine DCs) are 
more sensitive to the cytotoxic effects of the bacteria than human macrophages (as 
evident in trypan blue staining after exposure). Thus, optimal MOI for maximal 
staining of DCs is 35-50 (as opposed to 85-100 with macrophages). 
Using the manifest quantification permitted by this reporter gene model, we 
also undertook to compare the ability of our bacteria to deliver pSLICK-z to 
immature DCs versus mature DCs. Staining with x-gal revealed that the attenuated 
Salmonella targets immature cells more effectively than mature cells (not shown), an 
observation that is not surprising given the antigen-capturing, endocytosing function 
of immature DCs in vivo (131). 
We next chose to take advantage of the non-adherent nature of DCs, an 
experimental convenience that we did not have when working with macrophages. 
Thus, we could now manipulate and stain our target cells towards flow cytometric 
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Figures 23-25 Salmonella can be used to transduce human DCs in vitro such 
that they express a reporter gene Immature DCs were infected at MOI=50 with 
bacteria carrying either pTrc-B or pSLICK-z. Approximately 40 hours post-infection, 
cells were incubated with x-gal, a 8-galactosidase substrate. Cells exposed to 
bacteria carrying the prokaryotic promoter-driven vector (Figures 23A and 24A) 
show spotty, punctuate staining, suggestive of contained bacteria expressing the 
vector themselves within the cell DCs infected, on the other hand, with Salmonella 
carrying the eukaryotic promoter-driven vector at the same M O I show more 
widespread color, with a diffusely intracellular pattern, suggesting D C expression 
(Figures 23B and 24B). At higher magnification (Figure 25), a distinctly mature D C 
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analysis. Our initial use of the technology began once more with the /3-galactosidase 
reporter gene vectors. Instead of incubating the cells with x-gal, however, we 
incubated them with fluorescein di- /3-D-galactopyranoside (FDG), a fluorescent 
substrate of the enzyme. Our protocol here also involved incubation with verapamil 
(to block efflux of the reaction product), chloroquine (to inhibit endogenous 8-
galactosidase expression) and propidium iodide (to label dead cells) (See Chapter II 
for complete details). Flow cytometry results are shown graphically in Figure 26. 
Although we can appreciate the dose-dependency of protein expression seen 
with an increase in MOI, we may also note the limitation of cytotoxicity - evident, 
for example, in the relative scales of the y-axes in the two graphs. With MOI=50, 
there were far fewer viable cells within our analytical gate, which excluded DCs 
staining positive for propidium iodide. 
Nonetheless, the results of both /3-galactosidase studies involving DCs, like 
those of our macrophage experiments, are consistent with an effective Salmonella-
based plasmid delivery system. Infected DCs receive and express the vector carried 
by the bacteria, even as they are matured and activated. The risk of cytotoxicity can 
apparently be minimized by decreasing MOI. 
78 
Figure 26 Salmonella can be used to transduce human DCs in vitro such that 
they express a reporter gene Approximately 40 hours post-infection, D C s were 
incubated with fluoroscein di-8-D-galactopyranoside (FDG), a fluorescent substrate 
of 8-galactosidase, as well as verapamil (to minimize efflux of the reaction product) 
and chloroquine (to inhibit endogenous 8-galactosidase expression). Additionally, 
propidium iodide was added to allow us to gate specifically on living cells. Graphs 
on the left represent cells infected with bacteria carryingpTrc-8; graphs on the right 
reflect D C s infected with pSLICK-z. With the change in M O I , a dose-dependent 
effect can be appreciated. Furthermore, the change in y-axis scale suggests an 







Attenuated Salmonella can deliver a viral gene vector to human DCs: 
eukaryotic expression of HIV-1 gag detected by immunocytochemistry and flow 
cytometry 
We continued to explore our strategy using human DCs because we felt that it 
was important to confirm efficacy with this cell population. Once we had evidence of 
successful bacterial-assisted transfer of the plasmid encoding /3-galactosidase, 
however, we wanted to test the system using a vector containing a viral gene. 
Thus, we began this set of experimentation again by transforming aro A-
bacteria (14028) with a eukaryotic promoter-driven vector, this time a plasmid 
encoding HIV-1 gag (pVAXl/HIVgag). This vaccine vector is known to yield 
particularly high levels of expression in human cells in part because its genetic 
sequence was chosen on the basis of eukaryotic codon preference (See Chapter II 
regarding details of plasmid design and construction). 
Human PBMCs were isolated in the usual way, and DCs were cultivated as 
before. At this time, however, it was determined that the DCs could be more easily 
infected and manipulated in small tubes, rather than in wells (Figure 27). In this way, 
fewer cells were lost in washing. Once infected (at MOI=50), the cells were re-plated 
for overnight incubation. 
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Figure 27 The new protocol used to infect human DCs with Salmonella more 
effectively Cells were put into Eppendorf® tubes at 2 x 10 /500\iL, and incubated 
with loose caps. Spinning at 2000rpm x 5 minutes permitted more thorough washing, 
after which the cells could be re-plated at 10 /2mL culture medium until time of 
assay. 
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G E N T A M I C I N 
spin @ 2000 rpm x 5 min. 
re-plate IO6 / 2 m L 
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The first way in which w e chose to analyze the cells for viral gene expression 
was immunocytochemistry. For this purpose, we used a "cytospin" technique to 
mount DCs onto glass slides approximately 40 hours post-infection (See Chapter II 
for details). Cells were then fixed and blocked before being incubated with HIV-
infected patient's serum as a source of primary antibody. (This approach was chosen 
to be specific for HIV-1 subtype C, the same clade as the genetic source of the 
vector's gag insert.) 
Results of the staining are listed in Table 8 and illustrated photographically in 
Figures 28-30. 
D E N D R I T I C C E L L S I N F E C T E D A T 
M O I = 5 0 B Y .. 
Gag 
S T A I N I N G 
bacteria carrying an irrelevant plasmid (e.g., 
pSLICK-z) 
bacteria transformed with p V A X l /HIVgag 
- 1 % 
- 9 0 % 
Table 8 
Control cells in this study were infected with bacteria carrying an irrelevant plasmid 
(e.g., pSLICK-z). Immunocytochemical staining revealed dramatic visible 
differences between the two infectious categories, reflecting what we must conclude 
is broad, effective uptake and expression of the vaccine vector by the appropriately-
infected DCs. Indeed, on higher magnification (Figure 30), we can appreciate a 
certain deepening of the staining color in the perinuclear huff, suggesting a state of 
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active protein production (178), and consistent with the known trafficking and 
localization pattern of Gag in human cells (179). The high percentage (90%) of cells 
that stained positive for Gag expression is consistent with the relatively optimized 
conditions achieved in this study, including invasiveness of bacterial strain (14028) 
and expressiveness of vector (pVAXl with "codon-optimized" insert). 
We proceeded by evaluating the efficacy of bacterial pVAXl /HP/gag 
delivery in a second way, taking advantage once again of flow cytometry resources. 
In this study, we found that we could successfully employ a commercially-available 
antibody that was originally raised against HIV-1 subtype B p24. Despite clade 
differences, it seems that there is sufficient homology within gag across subtypes 
(180, 181). 
Thus, we again infected (MOI=35) human DCs with Salmonella carrying 
different vectors, then incubated them with the fluorophore-conjugated antibody (See 
Chapter II for protocol). The cells were ultimately fixed and assayed for protein 
expression using flow cytometry. Results are represented graphically in Figure 31. 
The flow cytometric measurement of relative levels of p24 (Gag) expression 
is consistent with our immunocytochemical results. We see that we can gauge DC 
expression of the foreign protein in both a gross histological way and in a more 
quantitative fashion. 
83 
Figures 28-30 Salmonella can be used to transduce human DCs in vitro such 
that they express a viral gene DCs were infected at MOI=50 with bacteria carrying 
either an irrelevant plasmid (Figures 28A and 29A) or pVAXl/HIVgag (Figures 28B, 
29B and 30), which encodes the viral gene under a C M V promoter. Cells were 
mounted on glass slides using a "cytospin " approach (in contrast to the cells 
illustrated in Figures 23-25). Hence, particulate matter seen represents an artifact of 
the technique, which affixes all contents of the medium to the slide at once. (Note that 
visible, unstained bacteria may serve as an additional control.) Immunocytochemical 
staining was carried out as previously, using patient serum as a source of primary 
antibody, and the Vectastain® ABC-AP kit for secondary antibody and substrate. 
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DISCUSSION 
As a general vaccine strategy, genetic immunization as it was originally 
conceived and tested requires augmentation and enhancement for true in vivo 
efficacy. With intradermal, subcutaneous or intramuscular administration of naked 
DNA, there is no targeted delivery to APCs (except perhaps Langerhans cells in the 
skin) (182-184). It has in fact been unclear as to which cells actually receive and 
express the genetic material, and which cells present the foreign antigens to T-cells. 
Indeed, much has been made of the "cross-priming" (185), or "direct" versus 
"indirect" priming (186) involved. Whatever the case, there seems to be a general 
consensus that steps must be taken towards improvement of the basic approach (182-
184). 
One obvious measure for strengthening the technique would be to ensure that 
DCs receive or manufacture the antigen themselves for presentation. A few groups 
have therefore already investigated the potential for DC delivery with DNA 
vaccination, whether intramuscular (168), subcutaneous (167, 168, 187) or intranasal 
(169). Intentional, directed targeting of DNA vaccines to immature DCs with a 
concomitant maturation stimulus, however, has not yet been achieved. 
As we have already considered (vide infra), immature DCs would have to be 
reached and simultaneously matured for a vaccine to induce immunogenicity and 
prime naive T-cells (131). It is therefore unlikely that any approach that falls short of 
this goal would yield protection from pathogenic challenge. In fact, in addition to the 
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Figure 31 Salmonella can be used to transduce human DCs such that they 
express a viral gene DCs were infected at MOI=z35 with bacteria carrying either an 
"empty" vector (pVAXl) or pVAXl/HIVgag, which uses a eukaryotic promoter to 
drive expression of the viral protein. Cells were then incubated with either an isotype 
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context of vaccination against infectious disease, D C s are also being actively 
investigated as tools of immuno-regulation for treating allograft rejection and 
autoimmune disease (188, 189). The need to provide a maturation stimulus for 
immunogenicity has also been illustrated in studies involving successful protein 
delivery to the DC receptor DEC-205. By conjugating a model antigen (OVA) to an 
antibody against DEC-205, Bonifaz et al. did effectively achieve significantly 
enhanced levels of DC presentation to T-cells. Without a maturation stimulus (in the 
steady-state), however, the effect of the DCs on the T-cells was tolerogenic; only 
when oCD40 was added did the delivery of antigen to DCs result in immunogenicity 
(190). Indeed, conjugation to oDEC-205 represents one promising strategy towards 
direct vaccine targeting to DCs in vivo. 
Other approaches to immunization involving DCs have involved attempts to 
prime T-cells against tumor antigens. Some of these studies have in fact already 
progressed to clinical trials (191, 192), though they generally involve ex vivo 
manipulation of the cells before re-infusion. 
Thus, a Salmonella-based carrier would certainly allow for some advantages 
over other vaccine strategies. We have shown here that the bacteria can not only 
deliver DNA vaccines directly to DCs, they also function as a maturation stimulus, 
themselves. The system would additionally almost certainly represent "direct" 
priming insofar as the APCs would be doing the expressing themselves - although 
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"indirect" priming would likely also be at play as a consequence of apoptosis and 
macrophage involvement. 
In addition to its untargeted administration, conventional DNA vaccination 
also requires improvement towards the generation of mucosal immunity (182, 184, 
193, 194), especially in challenging HIV-1 infection. Once again we must concern 
ourselves with DCs in this regard. Mucosal administration of a vaccine inoculum, 
alone, is insufficient to ensure mucosal responses. DCs are found throughout 
mucosal tissue, including in intranasal (195), buccal (196), tonsillar (197), tracheal 
(198), pulmonary (199), genital (200-202) and intestinal (102, 134, 203-207) regions. 
The possibility of tolerogenesis, however, must be avoided, as with any other route. 
In fact, oral administration in particular warrants caution in this regard, since the gut's 
natural function involves tolerogenic responses to antigens. 
One group therefore undertook to develop an appropriate adjuvant for use 
with an oral inoculum that would target and mature DCs directly. Williamson et al. 
found that co-administration of Flt-3L (with or without IL-1) successfully converted a 
tolerogenic oral inoculation into an immunogenic one (130). The adjuvant, however, 
was itself administered through an IP injection. 
More relevant to our purposes is a study that investigated the DC migration 
patterns within the gut in response to both cholera toxin (as an adjuvant candidate) 
and S. typhimurium. Both induced migration of DCs from the subepithelial dome 
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region of PP mucosa into underlying B- and T-cell rich follicles and adjacent 
parafollicular T-cell zones (208). Thus, our DNA vaccine delivery vehicles would 
likely permit appropriate and effective DC targeting, even within mucosal tissue 
following oral administration. 
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Chapter V I : 
Human dendritic cells, transduced using attenuated Salmonella 
typhimurium, can present foreign antigens to autologous T-cells in 
vitro 
INTRODUCTION 
The effort to design a vaccine against HIV-1 has necessitated careful 
consideration of precisely which viral antigens are optimal for protective 
immunogenicity. Studies involving both CD4+ and CD8+ responses have concluded 
that Gag epitopes are important (209-211); therefore, this protein has generally been 
incorporated into HIV-1 vaccine designs (212-220). 
Assays that have proven useful in evaluating the immunogenic strength of 
vaccine candidates include the ELISpot assay, as well as intracellular cytokine 
staining (ICS). Both approaches have been used to monitor the role of cytotoxic T 
lymphocytes (CTL) in viral infection, and can similarly be employed to quantify 
CD8+ T-cell responses to vaccines (221, 222), particularly in terms of IFN-y 
expression. 
When human subjects are not available to serve as donors of HlV-primed 
cells, it is more convenient to test vaccine strategies in the context of another viral 
infection. Influenza, therefore, represents a practical model system, as there is 
widespread exposure to (and vaccination against) this pathogen in the United States. 
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As a model antigen, then, influenza matrix protein (Ml) is an appropriate choice for 
experimental vaccine design, since it is highly conserved across types and strains 
(223-226), and it is the most abundant protein in the viral particle (226, 227). 
Furthermore, CTL responses to Ml are seen to confer protection from viral challenge 
in mice (228, 229). Indeed, the influenza-Mi model system has been useful in 
evaluating DC presentation of antigen to T-cells both in vitro and in vivo (229-233). 
Although HIV-1 certainly represents a very different sort of pathogen than influenza, 
and while AIDS pathogenesis is very distinct from the course of influenza infection, it 
is not inappropriate to test HIV-1 vaccine strategies in an influenza-based system. T-
cells that are primed against Ml are, for example, a practical tool for evaluating the 
basic potential for antigen presentation by autologous DCs targeted with a DNA 
vaccine. 
R E S U L T S 
Attenuated Salmonella can deliver a DNA vaccine vector to dendritic cells 
towards effective antigen presentation: autologous T-cell responses detected by 
ELISpot and flow cytometry 
We were interested in evaluating the potential for antigen presentation by 
human DCs transduced to express a foreign protein using attenuated S. typhimurium. 
We therefore isolated PBMCs from HIV-1 infected donors, then set up co-cultures 
involving DCs and T-cells. Gag peptide pools were used to pulse DCs as a positive 
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control. Other DCs were infected at MOI=35 with aroA- Salmonella (strain 14028) 
bearing a vector encoding HIV-1 gag (pVAXl/HIVgag). T-cell responses were 
assessed by staining cells for IFN-y an(l measuring expression using flow cytometry. 
Our initial studies proved impractical, however, because Gag-specific CD8+ 
T-cells failed to proliferate over time in vitro, even in co-culture with Gag-pulsed 
DCs. Indeed, it has been seen by others that CD8+ T-cells specific for viral antigens 
from most HIV-1 infected donors do not proliferate in co-culture (234), even with 
mature DCs present (235). 
We therefore turned to an alternative infectious context in which to monitor 
antigen presentation. It has previously been seen that most local healthy volunteers 
demonstrate CD8+ T-cell responses (by ELISpot and flow cytometry for IFN-y 
expression) specific for influenza (236). Thus, we designed a protocol for setting up 
DC/T-cell co-cultures towards IFN-y ELISpot and ICS analysis of T-cell responses 
(Figure 32). Blood samples from eight donors were ultimately processed as follows. 
PBMCs were isolated, then separated into CD 14+ and CD 14- populations (See 
Chapter II for details). The latter were kept frozen during the 6- or 7-day period 
required to cultivate DCs from the former. Before being seeded into a 96-well plate 
for co-culture (at a 1:30 ratio) with defrosted autologous T-cells, DCs were either 
infected with influenza as a positive control, infected with Salmonella (14028) 
bearing a vaccine vector (at MOI=35), or left unmanipulated as a negative control. 
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Figure 32 The basic protocol used to set up DC/T-cell co-cultures and detect 
effective antigen presentation PBMCs were isolated from whole blood, then 
subjected to C D 14+ selection using Miltenyi Biotec® magnetic beads (See Chapter II 
for details). C D 14- cells were frozen during the 6-7 days it took to cultivate DCs 
from the CD14+ cells using the cytokines indicated. DCs were incubated with virus, 
peptides, bacteria or plain cytokines before being seeded into co-culture with 
autologous T-cells (in either a 96-well plate or a 48-well plate, at a 1:30 ratio or 
1:60 ratio). Peptide and virus incubations were carried out just prior to seeding; 
infection with bacteria was carried out approximately 40 hours before seeding into 
co-culture. T-cell expression of IFN-y was analyzed at different time-points using the 



















Vaccine plasmids employed were either "empty" pVAXl (Invitrogen®) or an 
expression vector (pCAGGS) encoding influenza Ml protein. Assays for IFN-y 
expression were carried out at day 0 and day 10 or 14. 
Overall ELISpot results are shown in Figure 33. In general, co-cultures 
involving DCs that were infected with Salmonella carrying Ml vector yielded greater 
T-cell responses than co-cultures involving influenza-infected DCs. Co-cultures 
containing DCs infected with Salmonella bearing "empty" vector usually showed 
some T-cell responses at day 0, which diminished over time, revealing a significant 
gap between this category and co-cultures with DCs infected by Ml vector-bearing 
bacteria. Indeed, the initial IFN-y expression detected in co-cultures involving DCs 
infected by Salmonella carrying pVAXl could represent a memory response to the 
bacterial vehicle itself. In contrast to all three co-culture categories involving 
infected DCs, control DCs were seen to stimulate autologous T-cells to a minimal 
extent (Figure 33). 
A subset of the same donor samples was stained for intracellular IFN-y 
expression using a fluorophore-labeled antibody, then analyzed using flow cytometry. 
As with the ELISpot results, a greater difference between the IFN-y expression from 
co-cultures containing DCs infected by pVAXl -bearing Salmonella and co-cultures 
containing DCs infected by Ml vector-bearing Salmonella was seen as the co-culture 
was carried out for 10-14 days (Figure 34A and B). Additionally, it was confirmed 
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Figure 33 ELISpot assay results from antigen presentation studies using the 
influenza model system DC/T-cell co-cultures were set up at a 1:30 ratio in 96-well 
plates with DCs infected as indicated (MOI=35 for Salmonella). Cells were then 
assayed at different time-points using ELISpot, with re-stimulation (just prior to 
assaying) provided by the addition of autologous influenza-infected DCs, again at a 
1:30 ratio. Results shown in (A) summarize data from eight different donors at 
sixteen different time-points. (B) represents a single donor, illustrating the general 
trends observed. Co-cultures involving DCs infected with Salmonella carrying 
"empty" vector, for example, tended to display IFN-y T-cell responses early on, 
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Figure 3 4 Intracellular cytokine staining (ICS) results from antigen 
presentation studies using the influenza model system DC/T-cell co-cultures were 
set up at a 1:30 ratio in 96-well plates with D C s infected as indicated. Cells were 
then assayed at different time-points using ICS and flow cytometry, with re-
stimulation provided by the addition of autologous influenza-infected DCs. (A) shows 
data from one donor, illustrating the general pattern observed at early time-points 
(day 0 in this case), including relatively close levels of IFN-y expression between the 
two co-culture categories involving Salmonella-infected DCs. (B) illustrates how the 
gap between the two categories broadens over time (after 10 days in this case), with 
co-cultures involving D C s infected with Salmonella carrying M l vector yielding 
consistently higher levels of T-cell IFN-y expression. (C) illustrates the dominance of 
C D 8 + responses, even, as shown here, at day 0. 
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that most of the IFN-y expression was by CD8+ T-cells (Figure 34C). Neither the 
ELISpot data nor the ICS studies, however, revealed significant Ml-specific T-cell 
proliferation over time (i.e., expansion) in response to DCs infected with Salmonella 
carrying Ml vectors (Figure 33B, e.g.). 
In the course of working with the influenza/Ml model system, we came 
across an exceptional case that inspired us to explore innate immune responses in the 
context of the co-cultures (Figure 35). This anonymous donor displayed relatively 
robust Ml-specific T-cell responses, especially in cultures containing DCs infected 
with Salmonella bearing Ml vectors (Figure 35A). In staining for CD4 and CD8, 
however, it appeared that the EFN-Y-expressing T-cells were neither CD4+ nor CD8+ 
(Figure 35B and C). With our subsequent samples, therefore, we undertook to rule 
out NK and yd cells by staining for CD3 and yd, respectively (Figure 36). 
Responding cells in these cases were thus seen to be CD3+ and y<5-. Nonetheless, 
closer scrutiny of CD3 patterns (Figure 37 A) suggested that a more definitive 
investigation of the possible role of NK cells be undertaken. Subsequent samples 
were therefore stained for CD56 (Figure 37B). IFN-Y-expressing cells were thus 
consistently found to be CD56- (and yd-), which confirms that they are not NK cells. 
Indeed, Ml-specific IFN-Y-secreting T-cells were never again found to be CD8-
/CD4-; the donor that triggered our exploration of innate immune responses proved to 
be anomalous. 
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Figure 35 An interesting case of apparent non-CD8+/CD4+ responses to 
presentation of M l antigen The graphs illustrate data derived (at day 14) from the 
cells of one of eight anonymous donors, which were used to analyze D C presentation 
of influenza M l antigen to autologous T-cells. As seen in (A), this sample yielded 
relatively high levels of IFN-y expression in the co-culture involving DCs infected 
with Salmonella carrying M l vector. Staining for CD4 (B) and C D 8 (C), however, 
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Figure 36 Co-cultures stained for CD3 and y^ The previous case (Figure 35) 
inspired an exploration of the possible role of the innate immune system in mediating 
responses to D C presentation of M l antigen, particularly when Salmonella vehicles 
are involved. Co-culture cells were therefore stained for C D 3 (to rule out N K cell 
activity) and yd (to rule out yd cell activity). As illustrated, responsive T-cells are 
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Figure 37 Definitive flow cytometric exclusion of N K involvement in co-culture 
responses to D C presentation of M l antigen In comparing CD3 staining patterns 
between the two co-culture categories indicated (A), it appeared that cells exposed to 
DCs infected with Salmonella carrying M l vector expressed CD3 to a lesser extent 
than cells from co-cultures containing influenza-infected DCs. In order to definitively 
rule out N K cell involvement, therefore, cells were stained for CD56 (B). IFN-y-
secreting cells were thus seen to be CD56-, confirming that they are not NKs. 
(Indeed, no IL-2 was added to these co-cultures, making it unlikely that any N K cells 
would survive extended cultivation.) Similarly, IFN-y-secreting cells were 
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Any distinction in CD3 expression between IFN-Y-expressing T-cells from co-
cultures with influenza-infected DCs and T-cells from co-cultures with Salmonella-
infected DCs (Figure 3 7A) can perhaps be explained by a qualitative difference in 
maturation between the two DC populations: DCs that were pulsed with virus were 
first exposed to a cytokine cocktail (IL-6, IL-1 ft TNF-a and prostaglandin E2) in 
order to mature them. In contrast, DCs infected with bacteria were stimulated to 
mature only by the Salmonellae themselves, presumably through a TLR (121, 122, 
124). It is thus possible that the two pools of DCs attained different levels of 
maturation or activation, which, in turn, would have influenced the way in which they 
interacted with and activated T-cells. 
We decided to return to the HIV model system to confirm the ability of DCs 
infected by Salmonella vehicles to present vaccine antigens. In order to have an 
effective positive control, however, it was necessary this time to obtain blood samples 
from HIV-1-infected LTNPs, since it has been established that HIV-1-specific CD8+ 
T-cells proliferate in vitro only when derived from LTNPs (234, 235). Thus, we can 
use the extent of expansion of LTNP T-cells in co-culture with autologous Gag-
pulsed DCs as a standard of comparison (235) to T-cell proliferation in co-culture 
with DCs infected by Salmonella carrying DNA vaccine vectors. We therefore 
acquired blood samples from three known LTNPs, and proceeded to isolate PBMCs 
and set up co-cultures as before. Briefly, cells were subjected to CD 14+ selection 
towards DC cultivation, while CD 14- cells were frozen until the time of co-culture. 
Before the two populations of cells were united, immature DCs were either matured 
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with cytokines then left unmanipulated, matured with cytokines then incubated with 
Gag peptide pool, infected (at MOI=35) with Salmonella (14028) carrying pVAXl, 
or infected (at MOI=35) with Salmonella (14028) carrying pVAXl/HIVgag. The 
addition of maturation cytokines and infection with Salmonella were carried out 
approximately 40 hours prior to starting the co-culture; pulsing with Gag was carried 
out immediately prior to starting the co-culture. DCs were carefully washed (and re-
plated, when appropriate) before being seeded into the wells of 48-well plates with T-
cells at a ratio of 1:60. 
T-cells were sampled for analysis early in the co-culture (day 2-4) and again 
later on (day 9-10). At these time-points, cells were stained with fluorophore-labeled 
anti-IFN-Y antibody and assayed by flow cytometry to quantify expression of the 
cytokine. Results of the analysis of co-cultures from all three donors are shown in 
Figures 38-40. Cells were simultaneously stained for CD69 expression to better 
focus on activated T-cells. Early time-points suggest a general state of activation and 
secretion in response to Gag re-stimulation in vitro from all co-culture categories, 
including those containing mature but otherwise unmanipulated DCs. Later in the 
course of co-culture, however, we see, as expected, expansion of the responsive T-
cells in the positive control category, wherein DCs were pulsed with a Gag peptide 
pool. The T-cells from co-cultures involving DCs infected with Salmonella bearing 
gag vectors do not expand as much over time, though there still appear to be 
significant differences between this category and the T-cells from co-cultures 
involving DCs infected with bacteria bearing "empty" vector. On visual inspection of 
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Figures 38-40 Co-cultures derived from HIV-infected LTNPs Data from three 
different L T N P donors are illustrated. Cells were processed as before towards 
separation of D C s from T-cells. D C s were either left unmanipulated, pulsed with a 
Gag peptide pool, or infected (at MOI=35) with Salmonella carrying one of two 
vectors, as labeled. Cultures were set up in 48-well plates, with a D C : T ratio of 
1:60. Before assaying, all categories of cells were re-stimulated with Gag, plain 
medium or SEB, as indicated. Early co-culture time-points reflect general (evidently 
non-specific) T-cell activation and IFN-y secretion. Later time-points, however, show 
a decrease in T-cell responses from co-cultures involving unmanipulated DCs, and 
D C s infected with Salmonella carrying "empty" vector. Although specific T-cell 
populations from co-cultures involving Gag-pulsed D C s are seen to expand over 
time, responding T-cells from co-cultures involving D C s infected with Salmonella 
carrying gag vector do not consistently proliferate in vitro. Nonetheless, there is a 
consistent gap between the two Salmonella-infected D C co-culture categories at the 
later time-points. 
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the co-cultures, in fact, it could be appreciated that most of the DCs exposed to 
Salmonella were dying, and the corresponding co-cultures generally looked 
unhealthy. 
We therefore concluded that bacteria-induced cytotoxicity was interfering 
with, and ultimately preventing, effective DC presentation and consequent T-cell 
proliferation over time. We thus decided to lower MOI with our next pool of DCs for 
co-cultivation with autologous T-cells. The DCs of our subsequent blood sample 
were therefore infected with Salmonella carrying pVAXl/HIVgag at three different 
MOIs: 30, 15 and 5. Results of staining co-culture T-cells for IFN-7 expression are 
shown in Figure 41. Though the absolute degree of expansion at day 10 is only 
moderate, there is a clear inverse dose-dependency (in contrast to assays for 
expression), indicating that increased MOI probably results in a counter-productive 
degree of DC cytotoxicity. 
We proceeded to obtain four more blood samples from HIV-infected patients 
known to yield proliferative T-cell responses in vitro when restimulated with Gag-
pulsed autologous DCs (237). We decided at this time not only to greatly reduce our 
MOI, but also to slightly modify our co-culture protocol, as follows. We performed 
day 0 whole blood screenings for T-cell (CD4+ and CD8+) responsiveness to Gag re-
stimulation in vitro in order to establish a baseline potential for IFN-7 secretion. We 
then set up DC/T-cell co-cultures as before, but we now had sufficient cell numbers 
for a 1:30 ratio in the wells of 48-well plates. DCs were infected with Salmonella at 
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Figure 41 The effect of decreasing M O I on subsequent antigen presentation 
by DCs in co-culture As before, DC/T-cell co-cultures were set up using cells from 
a known HIV-infected blood donor. Co-cultures were again carried out in 48-well 
plates with a DC:T-cell ratio of 1:60. DCs infected with Salmonella carrying gag 
vector, however, were infected at three different MOIs this time, as indicated. The 
data reveal progressively increasing IFN-y T-cell responses as M O I decreases, 
suggesting more effective antigen presentation secondary to diminished cytotoxicity. 
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M O I = l , 2.5 and 5. Maturation cytokines were added to all DCs, including those 
infected with bacteria. Co-culture T-cells were analyzed for IFN-7 expression on day 
6. Results of ICS and flow cytometry are shown in Figures 42-45. 
The data suggest that an optimal balance was achieved between bacterial 
cytotoxicity and effective vaccine delivery towards antigen presentation. Indeed, the 
maximal degree of cytokine expression in response to DCs infected with Salmonella 
bearing gag vectors generally exceeds that in response to DCs pulsed with Gag 
peptide pool as a positive control. Additionally, the absolute peak levels of IFN-7 
expression seem to be greater from co-cultures involving DCs infected with 
Salmonella carrying pVAXl/HrVgag than from co-cultures involving Gag-pulsed 
DCs. 
One possibly significant experimental detail to consider here, however, is the 
addition of maturation cytokines to all DCs destined for co-culture, including those 
infected with Salmonella. This modification, intended to better control experimental 
conditions, reflects an approach that is distinct from previous co-cultures. Thus, we 
were not in this instance dependent on bacterially induced maturation of DCs for 
immunogenic readiness. Indeed, it may be useful in the future to examine the degree 
of DC maturation possible with infection at the low MOIs used in these studies. 
Although optimal responses appear on average to plateau with co-culture DCs 
infected at MOI =2.5, the results also seem to reflect qualitative and quantitative 
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Figures 42-45 Dramatic increase in effective antigen presentation with further 
reduction of M O I Blood from HIV-1-infected donors was once again processed for 
co-culture and ICS. Studies were streamlined to eliminate redundant positive (SEB) 
and negative (unmanipulated DCs) controls, in order to increase cell number for 
analysis. More definitive controls were provided by DCs pulsed with Gag peptide 
pool (positive) and DCs infected with Salmonella bearing "empty " vector (negative). 
After manipulation, DCs were seeded into co-culture with autologous T-cells at a 
1:30 ratio in 4 8-w ell plates. Cells from all four co-cultures were stained for IFN-y 
expression and analyzed by flow cytometry on day 6. (Gag peptide pool provided the 
re-stimulation.) Results from all donors reveal significant degrees of IFN-y 
expression from T-cells that were co-cultivated with DCs infected with Salmonella 
carrying gag vector. CD8+ responses are seen to plateau with MOI—2.5. 
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differences across individuals. One explanation for this phenomenon may simply be 
different medical histories of Salmonella exposure among the patients, since it is 
known that this may affect subsequent responses to the bacteria as vaccine delivery 
vehicles (238). Similarly, there are polymorphisms in the genes that encode host 
resistance factors in humans (89, 91, 93) such that individuals are likely to have 
distinct immunologic responses (and therefore vulnerabilities) to microbial 
pathogens, which would affect their reception to microbial vaccine vehicles. 
Finally, it has emerged recently that there is a continuum of memory CD8+ T-
cell subsets involving an eventual conversion of so-called "effector" memory T-cells 
to "central" memory T-cells. It is the latter subset that comprises cells that are 
capable of persisting and proliferating (239). We believe, therefore, that the 
expanding, IFN-7-secreting T-cell populations that we detect in our ICS assays are 
central memory T-cells. Thus, because our individual patients were sampled at 
different points in their infection and disease course, it is possible that their T-cells 
were assayed at different points in the effector to central memory continuum, and, 
thus, with different proportions of proliferative subsets present. 
DISCUSSION 
We chose to measure T-cell IFN-7 expression as a gauge of the potential for 
DCs infected with Salmonella carrying DNA vaccine vectors to present antigen. 
Accepting IFN-Yas an appropriate cytokine marker of memory T-cell activation (and, 
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therefore, of effective D C antigen presentation) presumes that it is an accurate 
indicator of functional (central) memory T-cell activity. Recently, however, some 
investigators have questioned the use of IFN-7 assays as definitive measurements of 
the immunogenic potential of vaccine candidates. 
Instead, a number of assays have been designed towards detecting actual 
cytolytic function, a return to the basis of the now largely disfavored 5lCr-release 
assay. These include measurements of perforin (234, 240), granzyme (240, 241), 
caspase-3 activity (242) and CD107a and b as a reflection of degranulation (243). 
Additionally, several groups have explored the utility of monitoring the expression of 
other cytokines, including TNF-a (242, 244) and BL-2 (235). Indeed, it has been 
noted that expression of cytokines such as IL-2, MIP-1/3, TNF-a and EL-4 dominate in 
response to effective vaccines against HBV and tetanus, not IFN-7(245, 246). 
Similarly, we must consider ultimately whether it is most appropriate to 
measure CD8+ T-cell responses in general as an indicator of immunogenicity. It has 
been demonstrated in the SlV/rhesus macaque model, for example, that viremia can 
be controlled even in the absence of CD8+ T-cells (247, 248). Furthermore, the 
recent prominent case of HIV-1 superinfection in the face of broad CD8+ T-cell 
responses (249) suggests that CD8+ T-cells may not play as critical a role in 
controlling infection as HIV vaccinologists previously thought. 
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Thus, it is perhaps relevant to note that immune responses detected in co-
cultures involving DCs infected by Salmonella carrying gag vectors include CD4+ 
activity, as well as CD8+ (Figures 42-45). Given the likely mechanism of DNA 
vaccine delivery by the invasive, intracellular bacteria, it is provocative to consider 
how the system might yield MHC class II-restricted antigen presentation. We may 
note, for example, that bystander DCs that internalize apoptotic cells and process their 
antigens for presentation do so to both CD4+ and CD8+ T-cells (78, 99, 100). 
Additionally, it is possible that the bacteria themselves express the eukaryotic vaccine 
vectors to some extent (48-53), which would certainly result in MHC class II-
restricted presentation by DCs. 
Perhaps the most significant conclusion we can draw from the data herein, 
therefore, is about the potency of DCs as APCs. We must accept, for example, that 
very few DCs are actually reached with infection at MOIs of between 1 and 5. 
Indeed, in our early studies aimed at assessing the degree of target cell expression as a 
reflection of functional vector transfer (See Chapters in and V), MOI was kept as 
high as possible (e.g., 50-100) in order to presumably reach the maximal number of 
APCs. In carrying out studies aimed at confirming antigen presentation, however, it 
was appreciated that widespread expression is not equivalent to widespread 
presentation; rather, DCs are largely rendered apoptotic as a consequence of bacterial 
invasion. Thus, in reducing MOI, we can preserve the viability of the small fraction 
of DCs that are reached and invaded by the Salmonella carriers. 
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The fact that such a small population of D C s can have such a significant effect 
on T-cells is not surprising. It is well-established, in fact, that very few DCs are 
required in order to activate literally thousands of T-cells (131, 250). Furthermore, 
although DCs are the primary APCs of the body, they constitute <1% of the total cell 
population of lymphoid tissue (71). The system of vaccine delivery evaluated in the 
present study can thus serve in part to illustrate the relative functional importance of 
DCs among the cells of the immune system. Moreover, the apparently successful 
antigen presentation achieved here clearly suggests that targeting DCs may be 




HORIZONTAL GENE TRANSFER 
We have known for 60 years that functional DNA can be transferred from one 
organism to another, thereby changing the genetic character of the latter (251). The 
potential significance of horizontal gene transfer was not fully recognized until the 
1950s, however, when bacterial multi-drug resistance emerged on a global scale. It is 
now understood that horizontal (or "lateral") gene transfer has played an integral role 
in the evolution of bacterial genomes (252). In eukaryotic phylogeny, too, horizontal 
gene transfer has apparently occurred with important evolutionary consequences. 
Indeed, in the years since the first full genome sequences were made available, there 
has been renewed interest in the topic (253-257). 
Among unrelated species, gene transfer is infrequently observed. Rarely, for 
example, have we seen spontaneous genetic exchange between prokaryotes and 
eukaryotes. One well-documented case of such an anomaly is the induction of tumors 
in higher plants by Agrobacterium tumefaciens, wherein a bacterial plasmid is taken 
up and expressed by a plant cell (258). 
The first documented evidence of direct transfer of cloned genes from bacteria 
to mammalian cells was reported in 1980 (259). Expression of the plasmid gene was 
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detected very infrequently, however, and appeared to be a consequence of sporadic 
phagocytosis. Many years later, another group reported genetic transfer from wild-
type Listeria and, to a lesser extent, Shigella to mammalian cells in vitro (67). 
It was not until 1995 that attenuated bacteria were intentionally manipulated 
towards the targeted delivery of DNA to eukaryotic cells (58). With this innovative 
approach, a new paradigm for vaccination was born: that of a facilitated genetic 
immunization, or bacterial transduction. Although integration into the target cell 
genome is not involved (as with a retrovirus), we feel that the use of a "third party" to 
deliver genetic material ultimately warrants such a term. Thus, the bacteria employed 
as transducers are "vehicles," rather than "vectors," as they are not intended to 
express the extra-genomic DNA they carry themselves. 
B A C T E R I A L T R A N S D U C T I O N 
It has been known for decades by bacteriologists that intracellular bacteria 
(including Mycobacteria, Chlamydia, etc., as well as Salmonella) manage to survive 
within phagosomes (58, 260-263). When we first undertook to develop Salmonella as 
plasmid-delivery vehicles, however, we could only speculate as to precisely how the 
attenuated bacteria might accomplish the task (Chapter DI, Figure 1). Although the 
mechanism of plasmid nuclear import remains a mystery, Salmonella persistence and 
avoidance of lysosomal degradation within its host cell is now a well-understood 
phenomenon. 
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Upon invasion, Salmonella immediately begins to shield itself from host cell 
defenses by using its virulence system. It controls its intracellular niche, the 
Sa/mo«e//a-containing vacuole (SCV), through the activity of various bacterial 
proteins, particularly those encoded by the Salmonella Pathogenicity Island 2 locus 
(SPI-2). Thus, the SCV is effectively segregated from the cell's degradative pathway 
throughout the life-span of the bacteria (43). 
SCVs are actively maintained by Salmonella-induced filament (Sif) A, which 
is expressed by the SPI-2 Type Three Secretion System (TTSS) (42, 43). 
Furthermore, the SCV is matured by the bacteria in a rab7 GTPase-dependent manner 
(264, 265). 
Importantly, another SPI-2 TTSS protein, SpiC, interferes with intracellular 
trafficking (266), preventing phagosomal-lysosomal fusion (267). Bacterial Sif 
proteins work further to prevent SCVs from proceeding to late endosomes, and even 
interfere with the trafficking of non-Salmonella-containing vesicles (268, 269). 
Additionally, it has specifically been revealed that SPI-2 TTSS proteins prevent all 
contact between SCVs and NADPH oxidase-containing vesicles (270-272). In fact, 
Salmonella uses enzymes to defend itself from oxidative stress, including superoxide 
dismutase and glucose 6-phosphate dehydrogenase (43). 
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Remarkably, it has recently emerged that the bacteria restore cytoskeletal 
architecture once within their protected SCVs. Releasing a protein called SptP, 
Salmonella reverses the cellular changes induced by its invasion (273). Finally, it is 
also now known that most of the recently elucidated bacterial survival strategies 
probably apply to persistence within DCs, as well as macrophages (274), though most 
relevant studies have involved macrophages or macrophage cell lines. 
Although we now understand that aroA- Salmonella probably remain within 
vesicles until they perish intracellularly (Chapter ID, Figure 1), it remains unclear 
how the plasmids they deliver are imported into the eukaryotic nucleus. Assuming 
that the delivered DNA is released directly into the cytoplasm once the bacteria lyse 
and the vesicular wall dissipates, it must be transported into the nucleus for 
transcription to occur. With subsequent translation in the cytosol, the foreign protein 
would be degraded by the proteasome, and resulting peptides shuttled into the 
endoplasmic reticulum (ER) by transporters-associated-with-antigen-presentation 
(TAP) for MHC class I presentation (275). This endogenous pathway is, in fact, what 
is assumed to occur with conventional, untargeted DNA vaccination once the injected 
plasmids are taken up by APCs (276), although it is recognized in this case that the 
majority of DNA is rapidly degraded by nucleases (277). 
A more appropriate, parallel model to consider would be the use of a so-called 
"gene gun" for DNA vaccination. This technique involves affixing the vaccine 
plasmids to gold particles before inoculation (278). Similarly, different kinds of 
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D N A microparticles have been produced for use in immunization (279, 280). It is 
thought that such a formulation permits direct delivery to APCs, which phagocytose 
the synthetic particulate matter. Furthermore, gold or microparticles would protect 
the DNA from extracellular degradation and possibly allow for mucosal 
administration (279, 280). Presumably, the DNA particles enter the phagosomal-
lysosomal pathway towards intracellular degradation. While foreign non-DNA 
components could in theory be presented on MHC class D molecules, the DNA itself 
is apparently imported into host cell nuclei and expressed. Encoded proteins are then 
presented on MHC class I molecules (279). 
The use of attenuated Salmonella to carry DNA vaccines, therefore, would 
allow for similar mechanistic advantages. As an adjuvant, Salmonella not only 
permits for targeted delivery through passive phagocytosis by APCs, but also by 
active invasion of them. Furthermore, like microparticles, bacterial vehicles protect 
DNA from premature extracellular degradation. Additionally, unlike synthetic 
formulations, Salmonella bears components that have naturally evolved as 
immunostimulants, including LPS as well as unmethylated sequences in bacterial 
DNA (281). Finally, as discussed previously (See Chapter IV), Salmonella vehicles 
allow for the mucosal administration of DNA vaccines directly to inductive sites. 
In general, a system of bacterial transduction as a vaccine strategy offers 
considerable promise for in vivo use. Apart from the built-in adjuvant functions 
described, Salmonella is a practical tool because of its well-understood genetics and 
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physiology. Indeed, live attenuated Salmonella typhi is already in use as a vaccine 
against typhoid fever (27). Furthermore, infection with attenuated strains is easily 
controlled with antibiotics, which provide a "safety net" in the event of any systemic 
toxicity (e.g., from LPS) or reversion to wild-type virulence. 
Nonetheless, certain potential complications and confounders of the approach 
must also be considered. Perhaps the greatest threat to in vivo efficacy that has 
emerged from in vitro experimentation is cytotoxicity: As we have seen, Salmonella 
infection can induce apoptosis of APCs. In vivo, however, this effect may not prove 
too much of a hindrance to effective antigen presentation, since uninfected, healthy 
bystander DCs can cross-present (97-100). Furthermore, we may conclude from the 
studies at hand (See Chapter VI) that there are sufficient numbers of viable DCs to 
effectively present vaccine antigens to autologous T-cells, even with a very low MOI. 
Another theoretical obstacle to using a Salmonella-based vaccine strategy in 
vivo is the possibility of pre-existing immunity to the bacterial vehicles themselves. It 
is known, however, that immunity against one strain or serotype of Salmonella does 
not protect against infection with another (282, 283). Thus, an individual previously 
infected or inoculated with S. typhi would not raise a memory response against S. 
typhimurium. More recently, it has been seen in the context of recombinant vaccinia 
vectors that pre-existing systemic immunity can be overcome by mucosal 
immunization (193, 194, 284), a phenomenon that may also apply to Salmonella. 
More specifically, however, investigators have found that prior immunologic 
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experience with either a homologous or heterologous strain actually potentiates the 
subsequent serum and mucosal antibody responses directed against foreign antigens 
delivered by recombinant Salmonella (101, 238). Thus, prior exposure to Salmonella 
as a pathogen or a vaccine should not preclude its subsequent use as a carrier for 
DNA vaccines against other pathogens. In fact, immunologic experience with 
Salmonella may enhance the subsequent response to a foreign antigen encoded by a 
Salmonella-delivered vector (101). 
Another concern regarding DNA vaccination in general is the risk of 
integration into the host cell genome, which may promote oncogenesis. While 
immunization with naked DNA has not been found to lead to genomic integration 
(285), delivery of eukaryotic expression vectors by invasive E. coli (286) and 
attenuated L. monocytogenes (61) has been reported to yield some chromosomal 
integration in vitro. This occurrence may be a consequence of the high plasmid copy 
numbers delivered to each cell by the bacteria (281). The risk for integration with use 
of bacterial vehicles in vivo is not yet known. It should be recalled, however, that 
transduced cells are probably fated to die, either from the apoptotic effects of 
Salmonella invasion, or from CTLs that respond to their presentation of foreign 
antigens (derived from the DNA vaccine or the bacterial carriers themselves). Thus, 
the risks associated with chromosomal integration may be averted in vivo. 
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F U T U R E P R O S P E C T S 
Developing the strategy of bacterial transduction as an approach to 
vaccination would require that we reach the optimal balance of maximal 
immunogenicity and minimal toxicity in vivo. The background of the carrier strain, 
the type of mutation selected to achieve attenuation, and the intrinsic properties of the 
immunogen itself would all have to be considered before proceeding to clinical trials. 
Any such aspect of the formulation could, alone, affect the extent and quality of the 
immune response elicited (287). 
Salmonella spp. are not the only bacteria that could be used in the system. 
Shigella, E. coli and Listeria, for example, have also been investigated as potential 
vaccine carriers (58, 59, 61, 62, 64, 288), and the relative advantages of the different 
species should be thoroughly explored. More importantly, perhaps, genetic 
modifications to the carriers could achieve greater efficacy. While Shigella and 
Listeria are known to actively escape from phagosomes, Salmonella and other 
candidate carriers could possibly be improved by engineering them to express an 
enzyme with phagosomal escape function, such as listeriolysin (281). 
In addition to strain choice, careful consideration must be given to the precise 
nature of the attenuating mutation, including the level of attenuation and stabilization 
of the attenuated phenotype. An auxotrophic mutation involving the biosynthesis 
pathway of purines or aromatic amino acids, for example, minimizes the virulence of 
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Salmonella (289). Other consequences of such mutations, however, should also be 
factored into the design of the system. It is known, in fact, that mutations affecting 
virulence properties of the bacteria tend to evoke different immune responses. Thus, 
different mutants may actually promote different T help patterns (287). 
Nonetheless, minimizing toxicity to the host is certainly paramount in 
choosing a vaccine delivery vehicle. A gram negative bacteria such as Salmonella 
could theoretically induce septic shock if it is not carefully modified. Thus, as a tool 
in cancer therapy, S. typhimurium mutants have been engineered to avoid inducing a 
systemic TNF-Q! based inflammatory response while retaining hyperinvasive 
properties thought to be desirable for efficacy (290). 
Dosing and vaccination schedule would also have to be experimentally 
determined. What is the minimum effective dose of bacteria needed to ensure in vivo 
transduction and antigen presentation? Does the priming need to be boosted? What 
are the in vivo kinetics of bacterial growth and persistence? (Is the administration of 
antibiotics necessary for timely elimination of the vehicles?) 
More important, of course, is the need to choose antigens wisely. A DNA 
vaccine against HIV-1, for example, is a significant challenge to design, even without 
considering method of delivery (13, 14). What permutation of viral genes should be 
included? (Should they be "codon-optimized" for increased eukaryotic expression 
and Rev-independent nuclear export?) Which vector backbone should be employed, 
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and with which eukaryotic promoter? Is a leader sequence necessary? In general, 
steps should be taken to maximize gene expression in situ and augment DNA 
vaccine-elicited immune responses, in addition to the adjuvanticity provided by the 
bacterial carriers. 
Development would also require in vivo studies prior to clinical trials. As we 
have seen, however, use of the murine model is limited and confounded by the 
cytotoxicity of S. typhimurium towards murine DCs. For the purpose of evaluating 
vaccine candidates against HIV-1, then, it would instead be more sensible to employ 
the rhesus macaque/SIV system. Although this non-human primate model has been 
very important for pre-clinical challenge studies of ADDS vaccines, it has recently 
been pointed out that improvements are required to more closely reflect the actual 
biological circumstances of HIV-1 infection in humans (4). Bearing this need in 
mind, however, it would indeed be useful to attempt in vivo immunization using 
bacterial transduction in macaques. 
In general, we feel that the use of Salmonella carriers to deliver DNA vaccines 
constitutes a powerful tool with which to improve the efficiency and augment the 
immunogenicity of basic genetic immunization. Because of its simplicity and 
economy, DNA vaccination has been especially attractive as a strategy for use in the 
developing world. With the additional advantage of oral administration, therefore, its 
potential utility is enhanced even further. Indeed, the system explored in this report 
offers an excellent prototypical design from which to base other such technologies of 
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genetic delivery. As an approach to immunization, specifically, it m a y predict the 
general future direction of vaccinology. 
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